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Abstract 
Although cognitive deficits are recognised as a core feature of schizophrenia, their trajectory over 
the course of the illness is still debated. The primary objectives of this thesis were: (i) to determine 
the neuropsychological profile at the first episode of psychosis (Chapter 3); (ii) to examine gender 
differences in the profile of neuropsychological performance (Chapter 4) and (iii) to determine if 
cognitive abilities decline, remain static or modestly improve throughout the course of psychotic 
illness (Chapter 5). 
 
The first (baseline) analyses form part the AESOP (Aetiology and Ethnicity in Schizophrenia and 
Other Psychoses) study, a population based, case-control study of first-episode psychosis 
recruited over a three-year period between September 1997 to August 2000 in London, Bristol 
and Nottingham. The second analyses (follow-up, where I followed 108 patients and 103 healthy 
controls) also form part the AESOP study, conducted 6 to 10 years afterwards but only in London 
and Nottingham. 
 
In this thesis I found that early in the course of psychotic illness cognitive deficits are present in all 
psychotic disorders, but are most severe and pervasive in schizophrenia and least pervasive in 
bipolar. There was strong evidence for gender differences in neuropsychological performance but 
these differences were disorder specific. Gender related factors appear to moderate the severity 
of cognitive deficits in bipolar/mania and depressive psychosis patients. Future schizophrenia 
patients had an early static developmental impairment on measures relying on knowledge 
acquisition (verbal IQ). This static deficit increases in size starting in late adolescence or early 
adult life. There was also an increase in deficit on memory functions. Future bipolar patients had 
normal or slightly above normal knowledge acquisition scores (verbal IQ) which started to 
deteriorate starting in early adult life. Thus, both schizophrenia and bipolar/mania patients show 
dynamic changes in general and specific cognitive functions which start early in childhood and 
continue across the life span. Both depressive psychosis and other psychotic disorders show 
different age related changes than schizophrenia or bipolar/mania. However because of small 
sample size and lack of studies examining the premorbid period therefore it is difficult to provide a 
life course model.  
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Chapter 1 An introduction to psychosis 
1.1 Introduction 
The term psychosis derives from the Greek words „psyche’ (the soul; the spirit; the mind) and 
„osis’ (denoting a process or condition, esp. a pathological state).  It refers to mental states where 
there is some loss of contact with reality and where there are disturbances to the normal process 
of thought perception. In 1845 Feuchterleben, coined the word „psychosis‟ in his book entitled 
“The Principles of Medical Psychology” where he proposed psychosis as a term for severe mental 
disorders (Beer, 1995). This concept has since undergone a number of refinements. One early 
definitional adjustment was the suggestion that psychosis represented a disease process (Ban, 
1976). In modern usage, the term psychosis refers broadly to severe psychiatric disorders, 
including schizophrenia, and some organic and affective disorders. Numerous criteria have been 
proposed to achieve a more precise definition, but there problems with all of them. In the fourth 
edition of the American Psychiatric Association‟s Diagnostic and Statistical Manual of Mental 
Disorders (American Psychiatric Association, 2000) it is emphasised that definitions of the term 
psychosis have never received universal acceptance. In the DSM-IV‟s broadest definition, 
psychotic symptoms consist of hallucinations, delusions, disorganised speech and grossly 
disorganised or catatonic behaviour. This more expansive symptom list is similar to those detailed 
in the World Health Organisation‟s Classification of Mental and Behavioural Disorders (World 
Health Organization., 1992) 
 
1.1.1 The functional and organic psychoses 
A fundamental distinction was made between the „organic‟ and the „functional‟ psychoses (Beer, 
1995) during the late nineteenth century. In organic psychoses, the emergence of symptoms 
arises from a clear pathology of the brain. Organic psychoses may occur as a result of cerebral 
hypoxia and brain lesions, metabolic and endocrine disorders, vascular abnormalities, infections 
and nutritional deficiencies. Organic mental disorders can be due to a general medical condition 
or to a brain disease such as Dementia of the Alzheimer‟s Type (DAT) or temporal lobe epilepsy, 
or to a psychoactive substance such as amphetamines or cannabis. By contrast in the functional 
psychoses, mental disturbances arise in the absence of any gross pathological changes to the 
brain or body. Primary functional psychotic disorders such as schizophrenia and affective 
- 14 - 
disorders do not have a clearly identified physical basis. In the present study, the research is 
focused on those disorders which are usually regarded to be functional psychoses. 
 
1.1.2 The symptoms of psychosis 
Positive and negative symptoms 
There is a general agreement that people suffering from psychosis may experience a collection of 
symptoms, which may be grouped as either positive or negative symptoms. Positive symptoms 
include: hallucinations delusions; disorganised speech or thinking and disorders of behaviour. 
They indicate the presence of mental activity not normally experienced. Table 1.1 provides the 
summary of the primary positive symptoms of psychosis listed in DSM-IV and ICD-10(American 
Psychiatric Association, 2000, World Health Organization, 1992). 
 
Table1.1 The positive symptoms of psychosis as defined by DSM-IV and ICD-10 
Hallucinations auditory, visual, olfactory, tactile 
Delusions (of) reference, persecution, nihilism, grandiosity, control, thought possession 
Disorganised speech stream of though, flight of ideas, loosening of associations 
Disorders of behaviour gross excitement/overactivity 
Motor abnormalities catatonia, gross psychomotor retardation 
 
Delusions are false beliefs that are firmly held on inadequate grounds; are not affected by rational 
argument or evidence to the contrary; furthermore it is not a conventional belief that the person 
might be expected to hold given her educational, cultural and religious background. Several types 
of delusions are recognised, either by the characteristics or the theme of the delusion. 
Hallucinations are perceptions experienced in the absence of an external stimulus to the 
corresponding sense organ. It differs from an illusion in being experienced as originating in the 
outside world (or sometimes within the person‟s body) but not within the mind (e.g. mental 
imagery). A hallucination can be in the mind, with an illusion there is a stimulus which is 
misinterpreted. Disorganised speech is normally inferred by examining abnormalities in speech. 
Disorders of behaviour or motor abnormalities comprise a marked increase in the normal levels of 
- 15 - 
activity, characterised by hyperactivity, or a marked decrease in activity, characterised by 
catatonia, or very slowed or fixed movements.  
 
Other symptoms associated with psychotic disorders include negative symptoms such as 
restricted emotional expression (flat affect), sparse language output (alogia), poor initiation and 
persistence of goal-directed behaviours (avolition), and inability to feel pleasure (anhedonia) 
(American Psychiatric Association, 2000). Negative symptoms are difficult to evaluate because 
they are non-specific, and may be caused by a variety of other factors e.g. medication side effects 
or mood-disorder (Skrabalo, 1999). They can appear more benign than positive symptoms as 
they are less distressing to the sufferer who may not even notice them but they are thought to 
predict a poor outcome. Although negative symptoms are an integral aspect of schizophrenia, 
neither the DSM-IV nor the ICD-10 explicitly defines negative symptoms as psychotic. Andreasen 
however, has argued that negative symptoms should be considered a fundamental aspect of 
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1.2 The classification of the functional psychoses 
1.2.1 Schizophrenia 
Schizophrenia is a severe psychotic disorder and one of the most common of the severe mental 
illnesses. Traditionally it was thought that it affects up to one percent of the world population at 
some point in their life (Jablensky, 2000, Jablensky et al., 1992). Using narrow definitions such as 
DSM-IV (American Psychiatric Association, 2000), it has an average lifetime prevalence of 0.7% 
(Saha et al., 2005), and primarily affects adults, being rare in children and becoming gradually 
more common during adolescence, with the peak age of onset in the early twenties in males, and 
three or four years later in females (Saha et al., 2005). Females show a later second peak around 
the time of the menopause (Saha et al., 2005). 
 
Emil Kraepelin carried out work towards the end of the nineteenth century that led to the 
description of the illness (Kraepelin, 1896). His dichotomy of the functional psychotic conditions, 
dementia praecox and manic-depressive insanity into separate disease entities was a landmark in 
the development of the schizophrenia concept. Dementia praecox was a progressive illness that 
often started in adolescence and followed a downhill course, possibly caused by organic changes 
to the brain. Manic-depressive insanity was a more treatable disorder, with periods of full recovery 
between episodes of the illness.  The dementia praecox notion was disputed by Bleuler (Bleuler, 
1950). He replaced this term with „schizophrenia‟ (meaning split or fragmented mind). The 
definitions in use today follow Kraepelin‟s dichotomy and use a syndromic diagnosis based largely 
on the work of Kurt Schneider (1887-1967), who proposed that certain „first-rank‟ symptoms were 
more reliable (but not necessarily essential) determinants of schizophrenia (Schneider and 
Hamilton, 1959). These symptoms - third person auditory hallucinations, thought interference, 
passivity and delusional perceptions – along with persistent delusions, catatonia, and negative 
symptoms, form the basis of the diagnostic criteria in ICD-10 (World Health Organization., 1992) 
and DSM-IV (American Psychiatric Association, 2000). However, the conceptualization of the 
„first-rank‟ symptoms has not solved the puzzle regarding the underlying aetio-pathology of the 
illness. One contemporary view of schizophrenia is one of a heterogeneous group of disorders 
(Hill et al., 1997). In this respect it is of note that the ICD-10 and DSM-IV (American Psychiatric 
Association, 2000, World Health Organization., 1994) recognise several sub-types of 
- 17 - 
schizophrenia including those described as „paranoid‟, „hebephrenic‟, „catatonic‟, „residual‟, 
„simple‟, deficit syndrome‟ and „undifferentiated‟.  
 
1.2.2 The affective psychosis (bipolar disorder and depressive psychoses) 
Kraepelin‟s dichotomy of the functional psychoses was subject to further elaboration when 
discrete entities within the class of manic-depressive insanity were proposed. In its original 
formulation, the term manic-depressive insanity included patients who suffered from depression 
only and patients who manifested both „poles‟ of affect (mania and depression) at different times. 
Leonhard (1957) was the first author to separate depression by polarity. He advocated a division 
of „bipolar‟ and „monopolar‟ disorders based on the nature of the recurrent episodes. A unipolar 
(depression only) – bipolar (depression and mania) distinction went into the DSM as the formal 
diagnostic criteria for affective disorders (Leonhard and Beckmann, 1999).  
 
Bipolar disorder 
Bipolar disorder has been described as a „continuum of phenotypes, ranging from a pattern of 
mild depression and brief hypomania to one of severe rapid cycling or predominantly mania with 
psychotic features‟ (Muller-Oerlinghausen et al., 2002). The presence of psychosis is not a 
requirement for a diagnosis of bipolar disorder. However, psychotic symptoms often occur in both 
the manic and depressive phases of bipolar disorder (McElroy et al., 1996). Specific sub-
categories are listed to distinguish bipolar disorder with or without psychotic symptoms in both the 
ICD-10 and DSM-IV. Bipolar disorder affects about 1 adult in 100 (National Advisory Mental 
Health Council, 1993; the prevalence in males and females is the same. Men appear to have an 
earlier onset than women with an average age of onset (in the United Kingdom) of 22 years and 
27 years, respectively (Kennedy et al., 2005).  
 
Patients with bipolar illness cycle through episodes of mania, depression and periods of euthymia 
(normal mood during periods of remission), and demonstrate a dramatic fluctuations in energy, 
social behaviour, mood and cognitive functioning. On some occasions, the disturbance consists of 
mood elevation, disorganised speech, hallucinations, delusions (usually grandiose), increased 
- 18 - 
energy, increased activity and irritability. This is known as a manic phase. Other episodes of 
disturbance which often follow a period of emotional euphoria and manic behaviour include a 
lowering of mood, marked reduction in activity and decreased energy. This is referred to as a 
depressive phase. For the diagnosis of bipolar disorder (with psychotic features) it is a 
requirement in both DSM-IV and ICD-10 (American Psychiatric Association, 2000, World Health 
Organization, 1992) that patients have experienced at least one episode of depression and at 
least one episode of mania. 
 
Depressive psychosis 
Depressive psychosis is an older term for what is now referred to in DSM-IV (American 
Psychiatric Association, 2000) as a "major depressive episode, severe, with psychotic features," 
and in ICD-10 (World Health Organization., 1992) as a "severe depressive episode with psychotic 
symptoms." This disorder includes symptoms of both depression and psychosis in an individual 
without an underlying diagnosis of a psychotic disorder. In a major depressive episode with 
psychotic features, the individual reports or exhibits false beliefs (delusions) and/or hears or sees 
things that aren't there (usually auditory but sometimes visual hallucinations). The delusions or 
hallucinations usually refer to depressive themes (mood-congruent psychotic features), such as 
the belief that one is responsible for the death of a loved one or that one is being punished 
because of a moral transgression. Hallucinations are usually temporary and may involve voices 
that berate the individual for perceived wrongs. Occasionally, the content of the delusions or 
hallucinations has no apparent relationship to depressive themes (mood-incongruent psychotic 
features) and may include delusions that one is being persecuted or that others can control one's 
thoughts. In general, mood-incongruent psychotic features are associated with a poorer prognosis 
than mood-congruent psychotic features. However, patients with severe depression will not 
necessarily develop psychotic symptoms (Elliott et al., 1996). It has been argued that psychotic 
depression is more than a simple manifestation of severe depression (Dubovsky, 1994). 
Approximately 10% to 25% of females and 5% to 12% of males are at a lifetime risk for 
developing a depressive psychosis, with only a small percentage of those exhibiting psychotic 
features. As in bipolar disorder, men appear to have an earlier onset than women with an average 
age of onset (in the United Kingdom) of 22 years and 27 years, respectively (Kennedy et al., 
2005). 
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1.2.3 Schizoaffective disorder 
Schizoaffective disorder is included in both the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (American Psychiatric Association, 2000) 
criteria and the International Classification of Diseases, Tenth Revision (ICD-10) (World Health 
Organization, 1992) coding. It is a perplexing mental illness that has both features of 
schizophrenia, including hallucinations, delusions, and distorted thinking, and features of a mood 
disorder, such as depression or mania. The coupling of symptoms from these divergent 
spectrums makes diagnosing and treating patients who are schizoaffective difficult.  
 
The diagnosis is made when the patient has features of both schizophrenia and a mood disorder. 
Unfortunately, it is often difficult to determine whether a patient has two separate illnesses 
(schizophrenia or a mood disorder), a combination of illnesses (schizophrenia with a mood 
disorder), or perhaps even a distinct and separate illness apart from schizophrenia or a mood 
disorder (Kane, 2010). 
 
1.2.4 Other psychosis 
In this category the disorders are conditions in which psychotic symptoms are present but they do 
not fulfil the criteria to make a formal diagnosis of schizophrenia, bipolar disorder, depressive 
psychosis or schizoaffective disorder. In the present study, the diagnostic grouping of other 
psychosis included persistent delusional disorders, acute and transient psychotic disorders, other 
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1.3 Aetiology of psychosis 
The aetiology of psychosis is not yet fully understood although both genetic and environmental 
factors have been implicated. 
 
1.3.1 Genetic factors 
Genetic susceptibility appears to be the most important influence in psychosis. Three lines of 
enquiry: family, twin and adoption studies have demonstrated that first degree relatives of an 
affected individual have 8-10 times the risk of the corresponding disorder in the general 
population. Most of the variance in risk for each disorder is genetic, twin studies revealing 
heritability for schizophrenia and bipolar disorder of around 80% or more (Cardno and Gottesman, 
2000, McGuffin et al., 2003) with largely unknown environmental factors also being involved. 
Given their high heritability and the difficulties inherent in direct physiological and pathological 
studies of living human brain, the identification of specific risk loci offers researchers one of the 
best chances of understanding pathogenesis. 
 
1.3.2 Brain structure 
A large number of imaging studies have shown that schizophrenia and psychotic bipolar disorder 
are associated with distinct grey matter deficits but anatomically coincident white matter 
abnormalities (McDonald et al., 2005, Meyer-Lindenberg, 2010). Individuals with schizophrenia 
have distributed grey matter deficit predominantly involving the fronto-temporal neocortex, medial 
temporal lobe, insula, thalamus and cerebellum, whereas those with bipolar disorder have much 
less significant regions of grey matter abnormality. Both groups have anatomically overlapping 
white matter deficits in regions normally occupied by major longitudinal and interhemispheric 
tracts. In chronic schizophrenia, more extensive volume reductions are observed in the cortex, 
particularly in medial and left dorsolateral prefrontal cortex, but also in the left superior temporal 
gyrus (Ellison-Wright et al., 2008). However in first-episode schizophrenia volume increases are 
restricted to parts of the putamen (Ellison-Wright et al., 2008). These increases are not heritable
 
(Goldman et al., 2008) and are probably a consequence of a number of environmental factors 
including antipsychotic drug action. 
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1.3.3 Neurochemistry 
Several neurotransmitters have been implicated in the development of schizophrenic symptoms 
including dopamine, serotonin and glutamate. Most recent theories on dopamine activity suggest 
a deregulation of dopamine neurotransmission (Howes and Kapur, 2009, Sunahara et al., 1993). 
They are based on the observation that dopamine agonists can induce psychotic symptoms 
(Ellison, 1994). The investigation of neurochemical abnormalities in the psychosis have indicated 
that the neurotransmitter serotonin and glutamate play an active role in their development (Howes 
et al., 2012, Javitt and Coyle, 2004).  
 
1.3.4 Environmental factors 
A number of studies have shown that obstetric complications (pregnancy and birth complications, 
abnormal foetal growth) are associated with increased rates of schizophrenia and other psychosis 
(Cannon et al., 2002b, Dalman et al., 1999). Whether obstetric complications initiate disruption in 
the brain development or are the consequence of pre-existing neural abnormalities remain 
unresolved (McGrath and Murray, 1995). Other possible early environmental insults include 
exposure to viruses influenza during pregnancy (e.g. (Rantakallio et al., 1997, Wright et al., 1995) 
and malnutrition (Susser et al., 1998). 
 
Drug abuse, such as amphetamine, is among other environmental risk factors occurring later in 
life, known to be able to trigger psychotic like symptoms (Chen et al., 2003). There is increased 
evidence suggesting modulating effects of cannabis on time of onset, severity and outcome of 
schizophrenia. Epidemiological studies have shown that early substance use (i.e. cannabis) 
among individuals who are at genetic risk may increase the likelihood of developing psychotic 
symptoms in adulthood. Caspi et al. provided evidence that those who carry the ValVal allele of 
the COMT gene and consume marijuana at an early age are at greater risk for developing 
psychotic symptoms later in life (Caspi et al., 2005). Furthermore, Smesny et al., found that the 
observed effects of cannabis on lipid metabolism in schizophrenia support the notion of gene x 
environment interaction (Smesny et al., 2007). Furthermore, Henquet et al., studies showed that 
- 22 - 
use of cannabis is associated with almost twice the risk for schizophrenia (Henquet et al., 2005a, 
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Chapter 2 Neuropsychology  
2.1 Basic concept in neuropsychology 
Neuropsychology has been defined as the „study of the relationship between brain function and 
behaviour. Neuropsychological assessment (i.e. administration of neuropsychological tests, test-
score analysis and interpretation of data) is a method of examining the brain by studying its 
behavioural product. Since the subject matter of neuropsychological assessment is behaviour, it 
relies on many of the same techniques, assumptions, and theories as does psychological 
assessment. The distinctive character of neuropsychological assessment lies in a conceptual 
frame of reference that takes brain function as its point of departure. Interpretation of performance 
data involves the determination of the presence or absence of a marked discrepancy between 
any two or more scores (Lezak, 1995, Silverstein, 1982). Thus, a corollary assumption in 
neuropsychology is that the analysis of marked discrepancies between levels at which a person 
performs different cognitive functions provides a window into the structure of normal cognitive 
systems that is, by the assumption that the results generated by this research activity will provide 
insights into the structure of cognitive mechanisms-and that it will ultimately provide important 
constraints for theories of the neural basis for cognitive functioning. Once the nature of 
neuropsychological impairment has been established, data from successive neuropsychological 
examinations repeated at regular intervals can provide reliable indications of whether the 
underlying condition is changing, and if so, how rapidly and in what ways. Once the nature of 
neuropsychological impairment has been established,  
 
The multidimensional and complex nature of most neuropsychological tests that, implicitly or 
explicitly, involve a number of different functions, makes it impossible to identify the specific 
deficits that underlie any given lowered test score without a systematic search for each 
component function that is involved in the neuropsychological test under examination (Keefe, 
1995). Also an inherent problem germane to individual neuropsychological functioning is that 
performance on many tests is usually influenced by several cognitive processes, despite the fact 
that an individual test may be differentially weighted to assess only one particular domain 
(Heinrichs and Zakzanis, 1998). An example of this is on the Trail Making Test (for a description 
of the task, see chapter 3). Evidence obtained from frontal lobe damaged patients, who were 
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impaired on this task suggests that the Trail Making Test –part A may reflect visual search 
whereas the part B may tap the executive domain assessing mental flexibility and set shifting. 
However, to complete this task successfully, a degree of attentional effort as well as motor and 
perceptual speed is required (Heinrichs and Zakzanis, 1998). The scores obtained therefore do 
not index a single cognitive function. 
 
Dating back to the work of Spearman (Spearman, 1961), a distinction has been made between 
general and specific cognitive abilities. Two widely used indices of generalised neurocognitive 
performance have been applied in schizophrenia research: general measures of intelligence 
quotient, or IQ, and composite scores or profiles derived from test batteries comprising multiple 
neuropsychological tests. Although both provide a measure of an individual‟s overall cognitive 
functioning, the results of these assessments often do not overlap to a substantial degree. 
Neuropsychological test batteries typically focus on assessment of multiple cognitive abilities, 
such as memory, executive functions, and attention, and these include a strong component of 
novelty of testing requirements. IQ tests, on the other hand, have a lesser emphasis on specific 
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2.2 Neuropsychology and psychosis 
Neuropsychological impairments are core features of schizophrenia and are related to functional 
status and other aspects of illness (Green, 1996, Heinrichs and Zakzanis, 1998) and although 
they are common in schizophrenia, they are not specific to this illness. They are evident also in 
the subjects with affective psychoses (Gilvarry et al., 2001, Goldberg et al., 1993, Gruzelier et al., 
1988, McGrath et al., 1997, Sweeney et al., 2000, Zubieta et al., 2001) schizoaffective disorder 
(Evans et al., 1999, Gooding and Tallent, 2002, Miller et al., 1996) and other forms of functional 
psychosis (Mitrushina et al., 1996, Zanelli et al., 2010). However, it appears that 
neuropsychological impairments are more severe in schizophrenia. In several studies, patients 
with schizophrenia have been shown to be more impaired in a range of cognitive tests than 
patients with bipolar disorder and other functional psychotic conditions (Gilvarry et al., 2001, 
Goldberg, 1999, Mitrushina et al., 1996, Seidman et al., 2002).  
 
Neuropsychological abnormalities are evident many years before the overt expression of any 
psychotic symptoms (Aylward et al., 1984, David et al., 1997, Davidson et al., 1999, Hoff et al., 
1999, Jones et al., 1994, Reichenberg et al., 2002). These cognitive symptoms are considerably 
developed at the time of the first psychiatric contact (Bilder et al., 2000, Saykin et al., 1994). First 
episode psychotic patients appear to have deficits in neuropsychological functioning that are 
similar to those seen in patients with chronic illness, although patients with poor outcome show 
some signs of deterioration in intellectual functioning in later life (Harvey et al., 1999a). Cognitive 
deficits are persistent and are observed at similar levels of severity even when symptoms have 
remitted (Addington and Addington, 1993, Barbarotto et al., 2001, Martinez-Aran et al., 2002, 
Silverstein et al., 1998). Similar, yet milder, abnormal neuropsychological performance has been 
observed in the non-psychotic relatives of schizophrenia patients (Cannon et al., 2000, Faraone 
et al., 1996, Goldberg et al., 1995, Goldberg et al., 1990, Keefe et al., 1994) and in patients with 
schizophrenia-spectrum conditions (Bergman et al., 1998, Mitropoulou et al., 2002, Moriarty et al., 
2003, Roitman et al., 2000, Trestman et al., 1995).  
 
Neurocognitive deficits do not respond markedly to treatment with atypical or typical antipsychotic 
medications despite the fact that these medications reduce the psychotic symptoms of the 
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disorder (Blyler and Gold, 2000). In addition, it has been demonstrated that abnormal 
neuropsychological functioning predicts a variety of aspects of poor functional outcome, including 
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2.3 Methodological issues in the application of neuropsychology in 
psychosis 
While there are a number of methodological issues pertinent to neuropsychological research, 
several factors of great importance need to be taken into consideration. 
 
2.3.1 Matching 
The issue of matching patients and healthy control participants on a number of background 
variables in order to control for confounding influences is an area of ongoing controversy 
(Goldstein, 1996a). On the one hand, association between performance on neuropsychological 
measures and level of education is almost unquestionable (Heaton et al., 1991, Heaton et al., 
1996). On the other hand, educational level is itself confounded by several variables including 
presence of psychotic disorder. 
 
Various premorbid indicators are used to match across, or controlled for and covaried through 
statistical means: age, socioeconomic status, education are a few examples of variables used. 
The rationale behind using premorbid indicators is that these variables may affect performance on 
cognitive tasks. 
 
The most common indicator of premorbid ability and hence matching criterion used in the 
literature is the National Adult Reading Test (NART) (Nelson and Willison, 1991). However, 
matching on this variable also does not escape confounding difficulties. When used in conditions 
such as schizophrenia, education achievement is usually curtailed at a young age which would 
obviously affect outcome. On the other hand, a similar concern with bipolar disorder seems 
unfounded, as bipolar patients are more likely to complete higher education (Torrey, 1999). 
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2.3.2 Medication 
The influence of medication has long been recognised as possibly disadvantageous to 
neuropsychological performance. In addition, psychotic patients are often treated with a cocktail 
of drugs at any given time. These can include antipsychotics, antidepressants, sedatives, and 
anticholinergics. All of these drugs affect multiple aspects of cognition (Lader, 1999, Minzenberg 
et al., 2004, Pachet and Wisniewski, 2003, Sharma et al., 1999). For example, antipsychotic 
treatment seems to improve some cognitive functions and to have a deteriorated effect on others 
(Rund et al., 1997, Rund et al., 1996, Spohn and Strauss, 1989). Anticholinergic drugs have been 
shown to impair some cognitive functions, such as verbal recall, independently of any 
autochthonous process of deterioration (Spohn and Strauss, 1989). 
 
On the whole, most studies employed to assess the effect of typical antipsychotics on cognition 
indicate a limited normalisation of some neuropsychological functions. For example, several 
literature reviews suggest a modest improvement in attention (Heaton and Crowley, 1981, Spohn 
and Strauss, 1989) and visuomotor function (Cassens et al., 1990). However, the results from a 
meta-analysis by Guilera et al., suggest that compared to typical antipsychotics, atypical drugs 
produce a slight improvement in the global cognitive index, and several cognitive domains show a 
slight improvement in the neuropsychological performance of patients (Guilera et al., 2009).  
 
Finally, in longitudinal studies, in which a great number of cognitive and neuropsychological 
functions have been assessed and the doses of antipsychotic and anticholinergic medication 
might have changed dramatically or been discontinued, it is a complex task to evaluate how the 
findings are affected by medication.  
 
2.3.3 Clinical symptoms 
Whether neuropsychological impairment merely reflects a transient state that passes with the 
alleviation of symptoms has been debated for many years. On balance, different cognitive 
domains may be affected differentially, depending on several variables such as first episode, 
chronicity, co-morbid substance abuse, illness severity (in terms of number of episodes and 
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degree of inter-episode recovery) and the polarity of the episode. Studies on first episode versus 
chronic patients, on clinically stabilised populations and on children at high risk of developing the 
disease suggest that cognitive impairment represent an integral part of the disease process 
(Goldberg et al., 1993, Hoff et al., 1992). Nonetheless, well-designed longitudinal studies 
evaluating changes in clinical state and the effect produced on neuropsychological performance 
are scarce. The inconsistency of many cognitive and psychosocial results reported may be partly 
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2.4 Aims of the study  
The objective of the study is to investigate baseline and trajectory of neurocognitive functioning in 
psychotic disorders. In the next chapter (Chapter 3) I will report the outcome of 
neuropsychological performance in the baseline study. Neuropsychological performance was 
compared between four major diagnostic groups with their first episode of psychotic disorders: 
schizophrenia, bipolar/manic disorder, depressive psychotic disorder, and other psychotic 
disorders. To examine specificity, the performance of each diagnostic group was compared with 
that of controls, followed by direct comparison of non-schizophrenia psychotic disorders with 
schizophrenia. Finally, the affective-psychotic groups are also compared. 
Based on the literature reviewed in Chapter 2.2, I tested the hypothesis that:  
 
Neuropsychological impairment will be evident across psychotic disorders but will be more severe 
in schizophrenia compared with affective psychosis (Reichenberg et al., 2009). 
 
In Chapter 4 I will investigate whether there are gender differences in the profile of 
neuropsychological performance in patients with first episode of psychosis. Because of the 
conflicting results in previous research, which examined cognition particularly in schizophrenia, no 
a priori hypothesis regarding gender differences in neuropsychological performance was made. 
The thesis describes methodology and presents the findings of the investigation with the aim of 
developing a greater understanding of the gender differences particularly in affective disorders. 
 
Finally in the Chapter 5 I will examine the following three questions:  
1) What is the trajectory of the cognitive impairment seen in psychosis after the first 
psychotic episode?  
2) Do all neuropsychological deficits follow the same trajectory?  
3) Do different psychotic disorders present the same trajectory of cognitive functioning?  
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Chapter 3 Neuropsychological profile in patients with first 
episode of psychosis  
3.1 Introduction 
Neuropsychological deficit is a key clinical feature of schizophrenia, and has also been found in 
association with other psychotic disorders (Bilder et al., 2000, Green and Nuechterlein, 1999, Hill 
et al., 2004) (Gold and Green, 2005). However, only a small number of studies have compared 
cognitive function between bipolar/ manic patients, schizophrenia, depressive psychosis, other 
psychotic disorder patients and healthy volunteers. 
 
The neuropsychological profile is typically characterised by prominent specific deficits, in memory 
and learning, executive functions, attention and processing speed, which are evident on a 
background of a generalized cognitive deficit (Palmer et al., 1997, Saykin et al., 1991). The 
majority of previous neuropsychological studies evaluating patients with first onset of psychosis 
compared to healthy controls have shown impaired performance in psychotic patients in several 
cognitive domains, including memory, executive functioning, attention, language, motor skills, and 
spatial ability (Addington et al., 2003, Bilder et al., 2000, Keefe et al., 2006, Mohamed et al., 
1999). These investigations have led to the proposition that schizophrenia should be seen as a 
disorder associated with generalized cognitive deficits (Bilder et al., 2000, Dickinson et al., 2004). 
However, there is no universal agreement on the latter notion, and there have been studies that 
highlighted executive functioning (Hutton et al., 1998, Riley et al., 2000) or verbal memory 
(Censits et al., 1997, Hoff et al., 1999, Saykin et al., 1991, Saykin et al., 1994) as the central 
feature of the cognitive impairment associated with schizophrenia. 
 
Although cognitive dysfunction is more severe in schizophrenia, patients with other functional 
psychotic disorders also demonstrate a disruption to normal cognitive processing. This is evident 
in the affective psychoses (Brown et al., 1994, Elliott et al., 1996, Gilvarry et al., 2001, Zubieta et 
al., 2001) schizoaffective disorder (Evans et al., 1999, Gooding and Tallent, 2002) and other 
forms of functional psychosis (Mitrushina et al., 1996). 
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Comparisons of the profile and magnitude of the neuropsychological deficits of patients with 
schizophrenia with those of patients with other psychotic disorders might have important 
implications for understanding the pathogenesis of these disorders, and for nosological models of 
psychotic disorders.  
 
Many reports have suggested that patients with other psychotic disorders also demonstrate a 
disruption of normal neuropsychological performance (Evans et al., 1999, Gilvarry et al., 2001, 
Gooding and Tallent, 2002). The majority of research has focused on the comparison of 
schizophrenia with bipolar disorder. While some studies show that patients with schizophrenia 
manifest more severe neuropsychological impairments (Goldberg et al., 1993, Schretlen et al., 
2007, Seidman et al., 2002) others did not detect differences in severity of impairments between 
bipolar psychosis and schizophrenia (Albus et al., 1996, Hoff et al., 1990). Furthermore, studies 
comparing neuropsychological performance between schizophrenia and psychotic depressive 
disorder are rare (Fleming et al., 2004, Jeste et al., 1996, Reichenberg et al., 2009).  
 
A major limitation of most previous studies is that they used clinical, rather than population based 
samples. Clinical samples include patient series, not complete populations of everyone with the 
disorder or symptoms. The clinical sample will be a subset of the population sample and can be 
biased by help seeking, referral bias and severity. The prognosis will tend to be worse and 
comorbidity more common. As a result, it is difficult to generalise from studies using clinical 
samples to everyone with the symptoms or disorder. Previous studies of first-episode patients 
were well done and sometimes had large samples. However, studies varied considerably in terms 
of the sources for case ascertainment (e.g., university clinics, referral centres or in-patient 
samples), and the age, duration of illness and medication status of patients. Moreover, while 
some studies used specific diagnostic groups, others examined heterogeneous groups. These 
issues further hinder the interpretation of this research, the validity of comparisons and the degree 
to which it can be generalised. On the other hand a population based sample will include milder 
variants or heterogeneous conditions with similar phenotypes hence there are also concerns with 
regard to generalising from a population based sample to a clinical one. 
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3.1.1 Aims and objectives 
Neuropsychological performance is compared between four major diagnostic groups with their 
first episode of psychotic disorders: schizophrenia, bipolar/manic disorder, depressive psychotic 
disorder, and other psychotic disorders. To examine specificity, the performance of each 
diagnostic group is compared with that of controls, followed by direct comparison of non-
schizophrenia psychotic disorders with schizophrenia. Finally, the affective-psychotic groups are 
also compared. Three features of my investigation are especially important. This investigation 
represents the largest epidemiological cohort of first-episode psychosis patients with 
neuropsychological data. Second, a large control sample was epidemiologically ascertained, 
enabling detailed and careful comparisons with patients. Finally, both patient and control samples 
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3.2 Materials and methods 
3.2.1 Study design  
The baseline analyses form part the AESOP (Aetiology and Ethnicity in Schizophrenia and Other 
Psychoses) study, a population based, case-control study of first-episode psychosis recruited 
over a three-year period between September 1997 to August 2000 in London, Bristol and 
Nottingham. Ethical approval for the AESOP study was granted by each region‟s appropriate 
Research Committee and each participant gave written informed consent after receiving a 
complete description of the study. 
 
3.2.2 The sample 
Cases 
The study (baseline) identified all cases aged 16-64 years with a first episode of psychosis (F10-
F29 and F30-F33 in ICD-10) who presented to specialist mental health services in tightly defined 
catchment areas in South-East London, Nottingham (between September 1997 and August 2000) 
and in Bristol over a nine-month period (September 1997 to May 1998). The South London 
catchment area comprised the former Bethlem and Maudsley NHS Trust areas served by the 
Maudsley Hospital and the former South Western Hospital. Those catchment areas represent a 
large area of South London encompassing the boroughs of Lambeth, Southwark and Croydon. 
Nottingham has well-circumscribed area served by a single provider of mental health services 
(Nottingham Healthcare NHS Trust). Finally, the Bristol area comprised the well-defined 
catchment area of the Avon and Wiltshire Mental Health Partnership NHS trust. 
 
All potential cases that made contact with psychiatric services for the first time (including adult 
community mental health teams, inpatient units, forensic services, learning disability services, 
adolescent mental health services, and drug and alcohol units) were screened. All potential points 
of contact with secondary psychiatric services (both in-patient and out-patient services) were 
regularly surveyed by phone or personal contact.  
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Identified participants were screened for the presence of psychotic symptoms with the „Screening 
Schedule for Psychosis‟ based on the Psychosis Screening Questionnaire (Bebbington and 
Nayani, 1995). This questionnaire explores the presence of a broad range of psychotic 
experiences. Participants positive for the Psychosis Screening  Questionnaire and who gave 
their written consent were then assessed with the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN 2.0) (World Health Organization., 1994). The SCAN is an instrument 
designed to enable the formulation or psychiatric diagnoses (Janca et al., 1994). Using the data 
obtained with the SCAN, consensus diagnoses were agreed for each participant. Those 
participants who did not meet the diagnostic criteria of a functional psychotic disorder according to 
the ICD-10 (1992) criteria were excluded from the study.  
 
The patients identified were then entered into further assessments if they satisfied following 
inclusion criteria: 
 Age 16-64 years. 
 Resident within the study area. 
 Absence of moderate or severe learning disability as defined by ICD10 (World Health 
Organisation, 1992b). 
 Presence of a functional psychotic illness (ICD10 F10-19, excluding coding F1x.0 for 
Acute intoxication; F20-29 and F30-39, psychotic coding) (World Health Organisation, 
1992b). 
 No previous contact with health services for psychosis. 
  
The exclusion criteria were: 
 Transient psychotic symptoms due to acute intoxication (as defined by ICD-10), following 
the administration of alcohol or other psychoactive substance. 
 Presence of a disease of the central nervous system. 
 History of head trauma resulting in loss of consciousness for over an hour. 
 An IQ of less than 50.  
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 Poor fluency in English language (cases were required to be native speakers of English 
or to have migrated to the UK by age 11). 
 
All assessments were conducted as soon as possible after initial presentation, as soon as 
participants were deemed able to sustain the interview by the responsible clinician. 
 
Healthy controls 
The study included a random sample of healthy controls with no past or present psychotic 
disorder, who were recruited using a sampling method that matched cases and controls by area 
of residence.  
 
Healthy individuals aged 16-64 were recruited using local press advertisements, household visits, 
and snowball sampling (i.e. the controls were asked to provide the names of other potential 
volunteers). The control sample also included a small number of Institute of Psychiatry and 
Maudsley Hospital staff. Participants identified were screened for the presence of psychotic 
symptoms with the Psychosis Screening Questionnaire (Bebbington and Nayani, 1995). 
Participants who rated positive for psychosis during this interview were also assessed by 
researchers trained in the SCAN to establish the presence or otherwise of a psychotic history. 
Only subjects negative for psychotic symptoms were entered into further assessment.  
 
Exclusion criteria for healthy individuals were: 
 Evidence of any psychotic disorder (past or present). 
 Presence of disease of the central nervous system. 
 History of head trauma resulting in loss of consciousness for over one hour. 
 An IQ of less than 50.  
 Poor fluency in English language (healthy individuals were required to be native speakers 
of English or to have migrated to the UK by age 11). 
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Participants who met the inclusion criteria where supplied with an information sheet describing the 
study and were reassured of the confidentiality of any information provided to the researchers. 
Only volunteers who gave their written consent were included in the investigation.  
 
Figure 3.1 The Analytic Cohort – baseline study 
 
AESOP Baseline Cohort 
                 Cases Controls 
Baseline cohort  592 412  
Non-Participants (refused or could not 
be contacted or spoke no English) 
 
202 
   
Consented  390 412  









Complete Neuropsychological Testing   245 264  
Excluded:    
 Poor English speakers – Likely to affect 
neuropsychological tests 
 Missing data on more than three 
neuropsychological measures 
 Diagnosis of schizoaffective disorder – 












Remaining in Analytic Cohort  187 177  
 
 
The derivation of the sample included in the analysis reported here is presented in Figure 3.1. 
The analytic cohort comprised of 187 subjects who had a consensus ICD-10 (World Health 
Organization, 1992) diagnosis of schizophrenia (N=65; F20), bipolar/mania (N=37; F30.2, F31.2, 
F31.5), depressive psychosis (N=39; F32.3; F33.3), or other psychotic disorders (N=46; including 
F22 Persistent delusional disorders, F23 Acute and transient psychotic disorders, F28 Other non 
- 38 - 
organic psychotic disorders and F29 Unspecified nonorganic psychosis), and 177 controls. For all 
cases and controls there was complete interview data as well as a) IQ measurements on the 
National Adult Reading Test (NART) (Nelson and Willison, 1991), and a short form of the 
Wechsler Adult Intelligence Scale – Revised (WAIS-R) (Wechsler, 1981); and b) a 
neuropsychological battery (see below). Cases and controls were required to be native speakers 
of English or to have migrated to the UK by age 11. The latter requirement ensured that each 
participant had a good command of English as a non-native language as they would have 
completed at least their secondary education in the UK, thus minimising the effect of linguistic or 
cultural biases on the performance of a multi-ethnic sample. In accordance with previous studies 
(Reichenberg et al., 2009) cases or controls with missing data on more than three 
neuropsychological measures were excluded.  
 
3.2.3 Diagnostic assessment and symptom data 
Clinical data were collected using the Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN) (Wing et al., 1990, World Health Organization., 1994). The SCAN incorporates the 
Present State Examination Version 10, which is used to elicit symptom-related data at the time of 
presentation. Ratings on the SCAN are based on clinical interview, case note review and 
information from informants (e.g. health professionals, close relatives). Researchers were trained 
in the SCAN interview on a World-Health-Organization (WHO) approved course and established 
pre-study reliability using independent rating of videotaped interviews. Principal investigators in 
each center produced independent diagnostic ratings on 20 case vignettes chosen at random 
from the entire sample. The kappa scores ranged from 1.0 for psychosis as a category to 
between 0.6 and 0.8 for individual diagnoses. ICD-10 diagnoses were determined using the 
SCAN data on the basis of consensus meetings involving one of the principal investigators and 
other members of the research team.  
 
Symptom ratings:  Symptom ratings were calculated according to the SCAN‟s Item Group 
Checklist (IGC) algorithm. The IGC combines scores from several SCAN items specific to a 
particular group of symptoms. For example: The IGC item, Special features of depressed mood 
includes feeling of loss of feeling, unremitting depression, morning depression, preoccupation with 
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catastrophe, pathological guilt, guilty ideas of reference, loss of self esteem and dulled 
perception. Scores for individual item groups range from 0 (absent) to a maximum of 2 depending 
on the frequency and severity of symptoms. Following a recent meta analysis (Demjaha et al., 
2009) individual item groups were aggregated into three symptoms dimensions: Negative 
Symptoms (Flat and incongruous affect, Poverty of speech, Motor retardation and Catatonic 
behaviour, and Nonverbal communication); Reality Distortion (Bizarre delusions and 
interpretations, Delusions of reference, Delusions of persecution, Experience of disordered form 
of thoughts, Nonspecific auditory hallucinations, and Non-affective auditory hallucinations), and 
Depression (Depressed mood, Depressive delusions and hallucinations, and Special features of 
depressed mood).   
 
3.2.4 Neuropsychological assessment 
Sixteen neuropsychological measures were selected to assess six domains: (1) Learning and 
Memory (verbal and visual); (2) Executive functions and working memory; (3) Attention, 
concentration and mental speed; (4) Language; (5) Visual constructual/perceptual abilities, and 
(6) WAIS-R verbal intelligence.  
 
3.2.4.1 Learning and memory domain 
Learning and memory were assessed using trials 1 through 5 (learning), trial 6 (immediate recall), 
and trial 7 (delayed recall), respectively, of the Rey Auditory Verbal Learning Test (RAVLT), and 
the Visual Reproduction sub test of the Wechsler Memory Scale - Revised (WMS-R) (Wechsler, 
1987).  
 
Rey Auditory Verbal Learning Test (RAVLT)  
The RAVLT ((Spreen and Strauss, 1991) p149-157) is useful in evaluating verbal learning and 
memory, including proactive inhibition, retroactive inhibition, retention, encoding versus retrieval, 
and subjective organization. The examiner reads list A of 15 words aloud at the rate of one per 
second to the subject who then has to repeat as many words as possible from the list - in any 
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order. This procedure is then repeated for trials A2-A5. After trial 5, the examiner presents a 
second list B of 15 words to the subject who then has to recall as many words as possible from 
word list B (this is trial B1). The subject is then asked to recall as many words as possible from 
word list A (without hearing word list A read out again) (this is trial A6). After a 20-minute delay 
period, filled with other activity, the subject is asked to recall the words from list A (again, without 
hearing word list A read out again) (this is trial A7). 
 
Visual Reproduction  
Nonverbal memory was assessed using the Visual Reproduction sub-test of the Wechsler 
Memory Scale Revised (WMS-R) (Wechsler, 1987). This is a visual recall test. It requires the 
subject to reproduce from memory simple geometric designs that were shown briefly (10 
seconds). There are three cards with designs adopted from the Army Performance tests and 
Binet. Scoring was calculated in accordance with Wechsler‟s guidelines (Wechsler, 1945, 1974). 
The largest obtainable score is 14.  
 
3.2.4.2 Executive functions and working memory domain 
Executive functions and working memory were evaluated using the Trail Making Test - part B, 
Letter-Number Span, and Sets AB and B of Raven‟s Coloured Progressive Matrices (CPM).  
 
Trail Making test (part B) 
This test measures attention, visuospatial tracking, and perceptual motor speed (Reitan, 1979, 
Reitan, 1985, Reitan, 1958, Reitan, 1992). Both parts of the Trail Making Test consist of 25 circles 
distributed over a sheet of paper. In part B, the circles include both numbers (1 – 13) and letters 
(A – L); as in part A, the subject draws lines to connect the circles in an ascending pattern, but 
with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The 
subject should be instructed to connect the circles as quickly as possible, without lifting the pen or 
pencil from the paper. Time the subject as he or she connects the "trail." If the subject makes an 
error, it is pointed it out immediately and allowed the subject to correct it. Errors affect the 
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subject's score only in that the correction of errors is included in the completion time for the task. 




The Letter-Number Span (Gold et al., 1997) is a task that is designed to measure verbal working 
memory. Subjects hear a list of numbers and letters and are instructed to repeat the numbers 
first, from smallest to biggest, then the letters in alphabetical order. The test has six levels with 
four trials at each level, for a total of 24 trials. The first level begins with a two-item string and 
each level increases the item-string by one, ending with a seven-item string. For example, a 
subject would hear "w7t4," and the correct answer is "47tw." Following a series of practice trials, 
the test involves 4 trials at each string length, beginning with 2-item strings (such as "m3") and 
proceeding up to 7-item strings (such as uc7g4qls") for a total of 24 items. Testing continues until 
the subject fails all four trials at a single level. The total number of correct responses (of 24 
possible) is used for the analyses. The test is terminated when a subject fails all 4 trials at any 1 
string length.  
 
Sets AB and B of Raven’s Coloured Progressive Matrices (CPM) 
Ravens Coloured Progressive Matrices (Spreen and Strauss, 1991) is a pattern based test 
relatively free of any language component that provides a „culture fair‟ estimate of cognitive 
functioning. It is a task of intellectual ability sensitive to fluid intelligence. The CPM Sets A, AB, B 
is arranged to assess mental development up to the stage when a person is sufficiently able to 
reason by analogy to adopt this way of thinking as a consistent method of inference. This 
apparently decisive stage in intellectual maturation appears to be one of the earliest to decline as 
the result of organic dysfunction. This test contains sets A and B from the standard matrices, with 
a further set of 12 items inserted between the two, as set AB. Most items are presented on a 
coloured background to make the test visually stimulating for participants. However the very last 
few items in set B are presented as black-on-white. In each test item, the subject is asked to 
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identify the missing element that completes a pattern. Many patterns are presented in the form of 
a 4x4, 3x3, or 2x2 matrix, giving the test its name. 
 
3.2.4.3 Attention, concentration and processing speed domain 
Attention, concentration and processing speed were measured using Trail Making - part A, and 
the WAIS-R Digit Symbol subtest.  
 
Trail Making test (part A) 
Trail Making Test (part A) Both parts of the Trail Making Test consist of 25 circles distributed over 
a sheet of paper. In Part A, the circles are numbered 1 – 25, and the subject should draw lines to 
connect the numbers in ascending order. 
 
WAIS-R Digit Symbol subtest  
WAIS-R Digit Symbol subtest from the Wechsler adult intelligence scale-revised (Wechsler, 
1981). The Digit Symbol task is used to assess psychomotor speed and involves auditory 
attention. It consists of (e.g. nine) digit-symbol pairs (e.g. 1/-,2/┴ ... 7/Λ,8/X,9/=) followed by a list 
of digits. Under each digit the participant should write down the corresponding symbol as fast as 
possible. Before beginning the test, participant gets to practice by completing the sample section 
(i.e. first 7 boxes on the worksheet). The number of correct symbols within the allowed time (90 
sec) is measured. 
 
3.2.4.4 Language domain 
Language was evaluated using verbal fluency: the Category (Semantic) Fluency (categories „body 
parts‟, „fruits‟ and „animals‟), and Letter Fluency (letters F, A, S).  
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Verbal fluency 
The Controlled Oral Word Association Test (Yeudall et al., 1987) was used to language. Category 
(Semantic) Fluency test entails the generation of words from a given category (body parts‟, „fruits‟ 
and „animals‟) within a pre-set time of 30 seconds. Letter Fluency (letters F, A, S) task. In this task 
participants are asked to generate as many words as possible that begin with a designated letter 
(F, A, S). This task is believed to emphasize the phonemic characteristics of words rather than the 
meaning of words. 
 
3.2.4.5 Visual-spatial perception and organisation domain 
Visual-Spatial Perception and Organisation were assessed using set A of Raven‟s Coloured 
Progressive Matrices and the WAIS-R Block Design.  
 
Set A of Raven’s Coloured Progressive Matrices 
Please see above 
 
WAIS-R Block Design subtest 
WAIS-R Block Design subtest from the Wechsler adult intelligence scale-revised (Wechsler, 
1981). The Block Design task is a measure of spatial ability and psychomotor speed. Participants 
have to visually analyse abstract figures from a series of printed two dimensional geometric 
patterns and then replicate the designs using a set of two-coloured cubes. 
 
3.2.4.6 WAIS-R verbal intelligence domain 
WAIS-R Verbal Intelligence was assessed by the WAIS-R Vocabulary and Comprehension sub 
tests. For a detailed description of measures see references: (Gold et al., 1997, Lezak et al., 
2004, Spreen and Strauss, 1991, Spreen and Strauss, 1998).  
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The WAIS-R Vocabulary subtest  
The WAIS-R Vocabulary subtest from the Wechsler adult intelligence scale-revised (Wechsler, 
1981). The Vocabulary test examines the individual‟s knowledge of word meanings and the ability 
to express those meanings verbally. Participants attempt to define a series of words presented to 
them both visually and orally.   
 
The WAIS-R Comprehension subtest 
The WAIS-R Comprehension subtest from the Wechsler adult intelligence scale-revised 
(Wechsler, 1981). The Comprehension test assesses common sense reasoning and the ability to 
deal with abstract social conventions, rules and expressions (e.g., "What does kill two birds with 
one stone metaphorically mean?"). It comprises a series of orally presented questions that require 
the individual to solve everyday problems or show understanding of social rules and concepts. 
 
3.2.5 General intelligence 
3.2.5.1 Premorbid intelligence 
Premorbid intelligence was estimated using the National Adult Reading Test (NART) (Nelson and 
Willison, 1991). The National Adult Reading Test is widely used to provide an estimate of 
premorbid intelligence. The NART is simple to administer and to perform. The person taking the 
test is asked to look at and pronounce, aloud, 50 words. None of the words fully follows the usual 
rules of English grapheme-phoneme correspondence or stress (e.g., ache, thyme, topiary). 
Therefore, if a person has not encountered the NART's words previously, applying normal rules of 
pronunciation will not lead to the correct answer. Scoring for this test is based on the number of 
errors made. The correlation between the NART generated IQ score and the WAIS-R IQ is very 
high (Crawford et al., 1991, Nelson and Willison, 1991). Discrepancy between the premorbid IQ 
from the NART and current IQ obtained on testing gives an estimate of intellectual deterioration. 
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3.2.5.2 Full-scale IQ  
Full-scale IQ was derived from the WAIS-R (Wechsler, 1981) subtests in the neuropsychological 
testing battery. The WAIS-R is one of the most extensively used tests of intellectual abilities. It is 
aimed at individuals aged 16 and older and has been standardised according to a range of adult 
bands. This study used a shortened version of the WAIS-R (Lezak et al., 2004, Spreen and 
Strauss, 1998). Short forms of the WAIS-R have been shown to produce an accurate estimate of 
full scale IQ (e.g. (Roth et al., 1984, Silverstein, 1982). This study included four subtests of the 
main WAIS-R battery: Vocabulary, Comprehension, Block Design and Digit Symbol. 
Combinations of these subtests also provide estimates for verbal IQ and performance IQ.  
 
3.2.6 Creating norms for neuropsychological tests. 
Neuropsychological tests often do not have good population norms that one can standardise test 
against and if they do these tests are not co-standardised (each test has norms from an entirely 
different control sample). To overcome this limitation, a regression based approach was used to 
create normative standards for the neuropsychological tests. Age, gender, ethnicity and education 
were regressed on each of the neuropsychological measures in the healthy sample. Then, scores 
were adjusted on the basis of these regression results and standard (i.e., Z) scores were created. 
The regression corrected scores were also inspected for both skewness and kurtosis. Only the 
Raven‟s test and Trail Making Test part A & B had significant skewness and these variables were 
log-transformed before standardisation. The same adjustment and standardisation procedure was 
applied to the patient sample, using the normative standards from the control sample. 
 
3.2.7 Data analysis 
Differences in socio-demographic and intellectual characteristics among the five groups were 
assessed using Analysis of Variance (ANOVA) models, Pearson Chi-Square or Fisher‟s Exact 
Test when appropriate. Differences in performance on each normative-adjusted 
neuropsychological measure between the five groups were examined using Analysis of Variance 
(ANOVA) models. The significance level was adjusted for multiple testing by Bonferroni 
correction, and was conservatively set at p≤0.003 (0.05/16). For descriptive purposes also the 
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following a-priori defined comparisons were carried out: First, each diagnostic group‟s 
performance was compared to the control group. Next, the following direct comparisons of 
performance between patients groups were conducted: Schizophrenia vs. Bipolar/manic; 
Schizophrenia vs. Depressive psychosis, and Bipolar/manic vs. Depressive psychosis. 
Significance level for these comparisons was set at p≤0.007 (0.05/7). Due to missing data on 
individual tests degrees of freedom varied slightly. Pearson‟s correlations were performed 
between each of the neuropsychological variables and three specific symptom dimensions: 
negative symptoms, reality distortion, and depression. ANOVA models were followed by analysis 
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3.3 Results 
3.3.1 Demographic characteristics 
Table 3.1 presents demographic characteristics of the cohort. There were significant group 
differences in age (F=15.6, df=4, p< 0.001). Post hoc analysis revealed patients with 
schizophrenia, bipolar/manic and other psychotic disorders to be significantly younger than 
controls. The groups also differed significantly in gender distribution, with an excess of males in 
the schizophrenia group (
2 
=12.73, df=4, p<0.013). All groups significantly differed in measures 
of education (
2 
=19.57, df=8, p<0.012) but not in ethnicity (
2 
=3.44, df=4, p=0.486). 
 
3.3.2 Current and estimated premorbid IQ 
There were overall significant group differences in current and estimated premorbid IQ (Table 
3.2). Descriptive analyses demonstrated that compared to controls the schizophrenia and the 
other psychotic disorders groups had significantly lower scores on current and estimated 
premorbid IQ. The depressive psychosis group had a significantly lower current IQ score. The 
schizophrenia group also had significantly lower IQ scores compared to the bipolar/manic group.  





























 Mean SD Mean SD Mean SD Mean SD Mean SD  
Age       26.54 8.39 29.04 9.61 36.97 12.86 28.08 8.09 37.24 12.87 0.001 
 N % N % N % N % N %  
Gender  (Male) 42 64.6 28 60.9 16 41.0 15 40.5 77 43.8 0.013 
                                    
Ethnicity  (White) 34 52.3 29 63.0 25 64.1 21 56.8 113 64.4 0.486 
Years of Education                    0.012 
11 (compulsory) 44 67.2 35 76.0 27 68.4 17 45.9 84 47.7  
12-13 (post-compulsory) 15 23.0 8 17.4 6 15.8 11 29.7 52 29.5  
14 or more (college, graduate 
or post-graduate) 
6 9.8 3 6.6 6 15.8 9 24.3 40 22.8  
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* - Differences reached the Bonferroni corrected level of significance (p≤0.007) 
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3.3.3 Neuropsychological performance  
3.3.3.1 Comparison between diagnostic groups and controls 
ANOVA models demonstrated that for 10 of the 16 measures overall group differences reached 
the Bonferroni corrected level of significance (p≤0.003). The measures that did not reach the 
Bonferroni corrected level of significance were Raven‟s set AB (p=0.0033), vocabulary (p=0.009), 
comprehension (p=0.009), and visual memory (p=0.044). No overall group differences were 
observed for the for Raven‟s A, and letter fluency (p-values>0.05).  
 
The neuropsychological performance profiles of the four diagnostic groups and results of the 
descriptive analyses that followed the ANOVA models and compared each diagnostic group to 
controls are presented in Figure 3.2. The schizophrenia group presented a widespread 
impairment, and performed worse than controls on all measures (all p-values < 0.05). For 12 of 
the 16 measures the differences also reached the Bonferroni corrected level of significance 
(p≤0.007) (see Figure 3.2). The depressive psychosis and other psychotic disorders groups also 
demonstrated widespread impairments. Differences reached the Bonferroni corrected level of 
significance (p≤0.007) for 8 and 6 measures respectively (Figure 3.2). In contrast, the 
bipolar/manic group performed significantly worse (p-values≤0.007) than controls only on 
measures of delayed verbal memory, and Category fluency (Figure 3.2).  














Filled symbols represent a statistically significant difference between the diagnostic group and healthy comparison group at a Bonferroni-corrected level (p≤0.007). 
Mean scores (comparison subjects set to zero) were calculated using all available diagnostic subjects per test (expressed in standardized [z] scores). Trail A=Trail 
Making Test, Part A; Trail B=Trail Making Test, Part B; Raven B=Raven‟s Coloured Progressive Matrices set B; Raven AB=Raven‟s Coloured Progressive Matrices 
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                       Figure 3.2 Neuropsychological performance among patients with various first-episode psychosis presentations a 
 
                                  Learning & Memory               Verbal         Processing       Executive Functions         Language     Visuospatial          
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Pearson‟s correlation coefficients were also examined across patients groups between 
neuropsychological test scores and symptom dimensions. More severe negative symptoms were 
associated with poorer performance on Vocabulary  (r=-0.193, p=0.041), Comprehension (r=-
0.193, p=0.043), Digit Symbol (r=-0.38, p=0.001), Raven‟s B (r=-0.231, p=0.018), Trail Making 
Test part A (r=-0.270,p=0.005), Trail Making Test part B (r=-0.207, p=0.036), Rey Total Learning 
(r=-0.238, p=0.014), Letter fluency (r=-0.284, p=0.006), and Category fluency (r=-0.242, p=0.02). 
More severe reality distortion was associated with poorer performance only on Trail Making Test 
part B (r=0.252, p=0.033). Severity of depressive symptoms was not significantly associated with 
performance on any neuropsychological test.  
 
3.3.3.2 Comparisons between diagnostic groups 
The bipolar/manic group performed better than the other patient groups on almost all 
neuropsychological measures. This group exhibited better performance compared to the 
schizophrenia group on measures of Vocabulary and Comprehension, Digit Symbol, Letter-
Number Span, and Block Design, and these were statistically significant at the Bonferroni 
corrected level (p-value ≤0.007).  
 
3.3.3.3 Role of general intellectual ability 
Differences in neuropsychological tests performance could be a function of current general 
intellectual ability (IQ). Therefore, in an exploratory analysis, I compared patient groups and 
controls while adjusting for current IQ. After adjustment, many of the specific neuropsychological 
differences were attenuated. None of the ANCOVA models reached a Bonferroni corrected level of 
significance, but a number of measures reached a conventional threshold of significance (p<0.05). 
These included the verbal learning (p=0.006), category fluency (p=0.004), and Letter-Number 
Span (p=0.017) tests.  
 
Descriptive analyses demonstrated that after adjustment for IQ the following comparisons were 
statistically significant at the Bonferroni corrected level of significance (p-value≤0.007). The 
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schizophrenia group was significantly impaired compared to controls on the Letter-Number Span 
(p=0.003) test. The depressive psychosis group was significantly impaired compared to controls 
on the verbal learning (p=0.003), category fluency (p=0.004) and Trail Making Test part B 
(p=0.006) tests. The other psychoses group was significantly impaired compared to controls on 
the verbal learning (p=0.003) test. The bipolar/manic group was significantly impaired compared to 
controls on the category fluency (p=0.003) test. Direct comparisons between the diagnostic groups 
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3.4 Discussion 
The aim of the first investigation was to compare neuropsychological performance between 
schizophrenia, bipolar/manic disorder, depressive psychotic disorder, other-psychotic patients and 
healthy controls. Despite extensive neuropsychological investigation in psychiatric disorders, this 
is the first epidemiological case-control investigation which includes a broad spectrum of psychotic 
patients with their first episode. The main findings of this investigation are that moderate to severe 
neuropsychological impairments characterize all psychotic disorders following the first psychotic 
episode, and that by-and-large, the magnitude of impairment on specific neuropsychological 
functions reflects a generalized cognitive deficit. Differences in neuropsychological performance 
between patient groups and controls, and between the different patient groups, were largely 
accounted for by differences in general intellectual ability.  
 
This investigation is novel in several ways. First, this is the first study to examine 
neuropsychological function in the category of other psychotic disorders, a large clinical group, 
which have been difficult to study. Second, this is an ethnically diverse sample. Third, the 
availability of a well characterised, large, epidemiologically ascertained control group (which is 
difficult to obtain), which increases the validity and generalisability of findings. Fourth, the 
diagnostic procedures were blind to neuropsychological assessment.  
 
Researchers have long debated the nature of the cognitive impairment in schizophrenia, 
particularly the relationship between cognition and psychosis, and whether schizophrenia is 
characterized by a generalized impairment versus independent deficits in specific cognitive 
impairments (Gold, 2004). Many neuropsychological investigations have sought to identify specific 
cognitive deficits that might represent more fundamental, so-called core impairments, reflecting 
underlying brain regions or networks related to the aetiology of the disorder (Jeste et al., 1996, 
Reichenberg and Harvey, 2007, Seidman et al., 2002). Similar investigations have been carried 
out with respect to other psychotic disorders. Determining if cognitive impairments are either more 
generalized across domains or more specific to particular domains also has important implications 
for clinical assessment, intervention design and genetic research (Gold, 2004). The results of this 
investigation highlight the degree of general cognitive impairment across psychotic disorders. 
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Studies of schizophrenia patients without a long history of illness or medication have documented 
a generalized deficit (Bilder et al., 2000, Gold, 2004, Mohamed et al., 1999), and these findings 
have been extended to chronic patients in a series of recent studies by Gold (Gold, 2004, 2008) 
that demonstrated that the cognitive deficit in schizophrenia is largely generalized across domains. 
Studies of generalized and specific neuropsychological functions in bipolar disorder and psychotic 
depression have been conducted in chronic patients (Quraishi and Frangou, 2002, Seidman et al., 
2002) and also suggest a generalized cognitive impairment.   
 
Despite the evidence in this investigation that the cognitive deficit in psychotic disorders is 
generalized across cognitive domains, additional, specific deficits were apparent. In schizophrenia, 
a selective deficit in working memory was evident. Working memory involves the ability to maintain 
and manipulate information over short periods of time, and has been associated with frontal-lobe 
function (Callicott et al., 2003, Reichenberg and Harvey, 2007). Deficits in working memory have 
been implicated as potential core deficits in schizophrenia (Elvevag and Goldberg, 2000), and 
working memory processes have been shown to share a genetic basis with schizophrenia 
(Toulopoulou et al., 2007).  
 
A deficit, beyond general intellectual impairment in verbal learning was evident in the psychotic 
depression and other psychoses groups. A selective impairment in memory and learning in 
schizophrenia has been previously hypothesized (Saykin et al., 1991), and has been associated 
with the temporal-hippocampal region (Reichenberg and Harvey, 2007). The lack of diagnostic 
specificity observed in this investigation merits further examination.  
 
The Category (semantic) fluency test was selectively impaired, beyond general intellectual 
impairment, in the psychotic depression, and bipolar/manic groups. This test involves the capacity 
to generate words belonging to a particular category and has been associated with frontal and 
temporoparietal function (Lezak, 1995). The letter (phonemic) fluency test was not selectively 
impaired. The disproportionate semantic fluency impairment may be due to abnormal semantic 
organization (Kremen et al., 2003).  
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Family, twin and molecular genetic studies suggest that schizophrenia and affective psychotic 
disorders may share certain susceptibility genes, and there is a clear overlap in phenomenological 
symptoms (Craddock et al., 2005, 2007, Murray et al., 2004). However, from a developmental 
perspective there are some differences. There is a large and consistent literature documenting 
childhood cognitive impairments preceding schizophrenia (Cannon et al., 2002b, Jones et al., 
1994, Reichenberg et al., 2002). Broadly defined affective psychosis has also been shown to be 
preceded by developmental impairment, but the effects are not as strong (van Os et al., 1997, 
Zammit et al., 2004), and seem to be confined to early-onset cases (van Os et al., 1997). 
Premorbid intellectual functioning was relatively intact in bipolar/manic patients in the present 
study as it was in the Dunedin cohort study (Cannon et al., 2002b). This may suggest that the 
onset of psychosis is associated with the appearance of a generalized deficit, superimposed upon 
a varying level of premorbid intellectual reserve, least in schizophrenia and greatest in bipolar 
disorder.    
 
This investigation has a number of strengths. It is a large first episode psychosis study 
incorporating a population-based epidemiological sample. The fact that a large normal comparison 
group was included also strengthens interpretation of the results. Limitations of this investigation 
should, however, be acknowledged. One limitation is that no patients were drug naïve. 
Unfortunately I had insufficient information on medication to reliably determine dosage. Medication 
type or side effects could influence subjects‟ neuropsychological performance. Nevertheless, only 
weak correlations between neuropsychological functioning and symptom severity were observed. 
Another limitation is that patients were assessed soon after their first admission. Diagnostic 
changes may occur over time. However, Schwartz et al. (Schwartz et al., 2000) followed up a 
large sample of first admission psychotic patients, and diagnostic consistency at 24 months after 
first admission was high for schizophrenia (92%), bipolar disorder (83%) and psychotic depression 
(74%). The most frequent shift in diagnosis at 24 months was to schizophrenia-spectrum 
disorders.  
 
In summary, these results add to the evidence indicating that early in their course, cognitive 
deficits are present in all psychotic disorders but are most severe and pervasive in schizophrenia 
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and least so in bipolar/manic disorder. They also add to the growing body of clinical, 
neurophysiological and genetic evidence supporting a continuum between schizophrenia and 
















- 58 - 
Chapter 4 Gender differences in the profile of 
neuropsychological performance in patients with first episode of 
psychosis 
4.1 Introduction 
It is well established that patients with schizophrenia and other psychosis exhibit a wide range of 
neuropsychological deficits (Reichenberg et al., 2009, Zanelli et al., 2010). An unresolved 
question, however, is whether there are gender differences in cognitive performance. The existing 
literature suggests that there are pronounced sex differences in schizophrenia, including 
differences in age of onset, clinical symptoms, brain structure and outcome (Narr et al., 2001, 
Shipman et al., 2009). For example, on average, males have earlier age of onset, longer and more 
frequent acute psychotic episodes, while females show better premorbid function, less negative 
symptoms, better response to antipsychotic medication and more positive symptoms (Rubin et al., 
2008, Shipman et al., 2009).  
 
In terms of neuropsychological function, evidence concerning schizophrenia is mixed. While some 
studies report less severe cognitive impairments in female patients on most cognitive domains 
(Dickinson et al., 2010, Goldstein et al., 1998, Leung and Chue, 2000) other studies found that 
females exhibited greater cognitive deficits (Lewine et al., 1996, Perlick et al., 1992). Some 
research failed to find any significant gender differences in cognition in schizophrenia (Andia et al., 
1995, Goldberg et al., 1995, Gur et al., 2000, Hoff et al., 1998, Shipman et al., 2009), and yet 
others reported domain-specific gender differences, with males showing greater impairments than 
females in sustained attention, language, executive function and intelligence (Goldstein et al., 
1998, Haas et al., 1991, Kopala and Clark, 1990, Seidman et al., 1997).  
 
The question of gender differences in neuropsychological function in other psychotic disorders has 
rarely been examined. Carrus et al (Carrus et al., 2010) reported that in bipolar patients, males 
underperformed females on immediate memory tasks (encoding and retrieval processes). Barret 
et al (Barrett et al., 2008) also noted that male patients underperformed female patients in 
measures of spatial working memory. These studies did not find gender differences in 
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performance on measures of planning, attentional set-shifting, verbal fluency, general intellectual 
ability, response inhibition and other executive functions.  
 
However most of the studies that examines neuropsychological function in psychosis by gender 
examined patients with established illness and thus performance may have been impaired by 
issues concerning treatment or illness course. In this investigation I examined gender differences 
in neuropsychological function in first episode patients with a range of psychotic illnesses, 
including schizophrenia, bipolar/manic and depressive psychoses. Four features of this 
investigation are especially important. First, this investigation examines a large epidemiological 
cohort of first-episode psychosis patients with neuropsychological data. Second, a large 
community control sample was epidemiologically ascertained, giving detailed and reliable norms 
for comparison. Third, a comparison across diagnostic groups is a unique feature of this 
investigation. Finally, both patient and comparison samples are ethnically diverse, thus increasing 
the potential generalisability of results. 
 
4.1.1 Aims and objectives 
The main objective is to investigate whether there are gender differences in the profile of 
neuropsychological performance in patients with first episode of psychosis. Because of the 
conflicting results in previous research, which examined cognition particularly in schizophrenia, no 
a priori hypothesis regarding gender differences in neuropsychological performance was made. 
The thesis describes methodology and presents the findings of the investigation with the aim of 
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4.2 Materials and methods 
4.2.1 The analytic cohort 
The analytic cohort comprised of male and female patients who had a consensus ICD-10 
diagnosis of schizophrenia or schizoaffective disorder (M=45, F=25), bipolar/mania (M=14, F=20), 
depressive psychosis (M=15, F=21) and 148 healthy controls (M=67, F=81). For all cases and 
controls there were complete interview data as well as: a) IQ measurements on the National Adult 
Reading Test (NART) (Nelson and Willison, 1991),
 
and a short form of the Wechsler Adult 
Intelligence Scale – Revised (WAIS-R) (Wechsler, 1981); and b) a neuropsychological battery. 
Cases and controls were required to be native speakers of English or to have migrated to the UK 
by age 11. The latter requirement ensured that each participant had a good command of English 
as a non-native language as they would have completed at least their secondary education in the 
UK, thus minimising the effect of linguistic or cultural biases on the performance of a multi-ethnic 
sample. In accordance with previous studies (Reichenberg et al., 2009), cases or controls with 
missing data on more than three neuropsychological measures were excluded.  
 
4.2.2 Neuropsychological assessment 
Sixteen neuropsychological measures were selected to assess six broad cognitive domains: (1) 
Learning and Memory (verbal and visual); (2) Executive functions and working memory; (3) 
Attention, concentration and mental speed; (4) Language; (5) Visual constructual/perceptual 
abilities, and (6) WAIS-R verbal intelligence.  
 
1. Learning and memory:  verbal ( short-term verbal immediate recall and delayed verbal 
recall) were assessed using trials 1–5, 6 and 7, respectively, of the Rey Auditory Verbal 
Learning Test (RAVLT) and  visual (immediate and delayed recall) was examined using 
Visual Reproduction of the Wechsler Memory Scale - Revised (WMS-R) (Wechsler, 1987). 
2. Executive functions and working memory were evaluated using the Trail Making Test - 
part B, Letter-Number Span, and Sets AB and B of Raven‟s Coloured Progressive 
Matrices (CPM) 
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3. Attention, concentration and mental speed were measured using Trail Making - part A 
and the WAIS-R Digit Symbol subtest.  
4. Language was evaluated using the Semantic Fluency (categories „body parts‟, „fruits‟ and 
„animals‟), and Letter Fluency (letters F, A, S). 
5. Visual-construction/perceptual abilities were assessed using set A of Raven‟s 
Coloured Progressive Matrices and the WAIS-R Block Design. 
6. WAIS-R verbal intelligence was assessed by the WAIS-R Vocabulary and 
Comprehension sub tests. 
 
Premorbid intelligence was estimated using the National Adult Reading Test (NART) (Nelson and 
Willison, 1991). Full-scale IQ was derived from the WAIS-R (Wechsler, 1981) subtests in the 
neuropsychological testing battery. 
(Full description; please see chapter 3.2.4 Neuropsychological assessment). 
 
4.2.3 Data analysis 
Gender differences in socio-demographic characteristics, symptom severity and measures of IQ 
among the three diagnostic groups were assessed using Analysis of Variance (ANOVA) models, 
Pearson Chi-Square or Fisher‟s Exact Test when appropriate. For descriptive purposes I carried 
the following a-priori defined comparisons: for each diagnostic group male and female patient 
performance on the normative-adjusted neuropsychological measures was compared to the 
performance of the control group using ANOVA models. Gender differences in performance on the 
normative-adjusted neuropsychological measure among the three diagnostic groups were 
examined using a Repeated Measures Analysis of Variance (ANOVA) model. Domain scores were 
computed as the average of scores of the tests comprising each of the six domains described in 
the previous section. These domain scores were used in the analysis. Due to missing data on 
individual tests, degrees of freedom varied slightly. ANOVA was used to examine gender 
difference on symptom dimensions: negative symptoms, reality distortion, depressive symptoms, 
disorganization and manic symptoms. 
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4.2.4 Creating gender-specific norms for neuropsychological tests 
A regression based approach was used to create gender-specific normative standards for the 
neuropsychological tests. This was done separately for males and females. Age, ethnicity and 
education were regressed on each of the neuropsychological measures in the healthy sample of 
males and females. Then, scores were adjusted on the basis of these regression results and 
standard (i.e., Z) scores were created. The regression corrected scores were also inspected for 
both skewness and kurtosis. Only the Raven‟s test and Trail Making Test part A & B had 
significant skewness and these variables were log-transformed before standardisation. The same 
adjustment and standardisation procedure was applied to the male and female patient sample, 
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4.3 Results  
4.3.1 Demographic characteristics 
Table 4.1 presents the demographic characteristics of male and female patients in the three 
diagnostic groups and healthy controls. The groups differed significantly in gender distribution 
(χ
2
=9.98, df=3, p=0.03), with a higher proportion of males in the schizophrenia group compared 
with the bipolar/manic and depressive psychosis groups. Gender differences in ethnic origin were 
only evident in the bipolar/manic group (χ
2
=5.55, df=2, p<0.018), with higher proportion of non-
white females. Age of onset was higher for females compared with males in the schizophrenia 
group (t=-2.58, p=0.012). There were no significant gender differences in level of education. 
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Table 4.1  Demographic characteristics of males and females patients with first-episode of psychosis and healthy controls 
 
 Schizophrenia Bipolar/Manic Depressive Psychosis Controls 
 Males Females Males Females Males Females Males Females 
 (N=45) (N=25) (N=14) (N=20) (N=15) (N=21) (N=67) (N=81) 
Age (±SD) 24.9±6.5 30.4±11.4 26.0±5.8 30.9±8.7 33.2±12.6 40.5±12.7 39.2±13.2 38.8±12.4 
Years of Education         
11  (compulsory) 64.4% 60.0% 35.7% 50.0% 53.3% 76.2% 38.8% 55.6% 
12-13 (post-compulsory) 28.9% 20.0% 50.0% 15.0% 20.0% 14.3% 32.8% 27.2% 
14 (college, graduate, 
post-graduate) 
 6.7% 20.0% 14.3% 35.0% 26.7%  9.5% 28.4% 17.2% 
Ethnicity Caucasian 
 
60.0% 60.0% 85.7% 45.0% 60.0% 66.7% 70.1% 81.5% 
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4.3.2 Current and estimated premorbid IQ  
Male and female current and estimated premorbid IQ in the three diagnostic groups are shown in 
Figure 4.1 Males and females were compared to controls on current and estimated premorbid IQ 
measures using ANOVA models. The significance level was adjusted for multiple testing by 
Bonferroni correction and was conservatively set at p≤0.0125 (0.05/4).  
 
Figure 4.1 Estimated premorbid and current (shaded areas) IQ in males (blue bars) and 
females (red bars) across diagnostic groups: schizophrenia (N=45 males, N=25 females); 
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4.3.2.1 Comparison to controls 
In the schizophrenia group, females performed significantly worse than healthy controls only on 
current IQ, whereas males performed significantly worse on both current and estimated premorbid 
IQ. In the bipolar/manic group there were no significant gender differences. In the depressive 
psychosis group, females performed significantly worse on current IQ compared with controls. 
 
4.3.2.2 Comparison of males and females within diagnostic groups 
Analysis of variance (ANOVA) revealed a significant effect of diagnosis on current IQ (F=7.298, 
df=2, 134, p=0.001), but no significant effect of gender (F=1.674, df=1, 134, p=0.198). However, 
there was a significant gender by diagnosis interaction effect (F=4.216, df=5, 134, p=0.017), 
where females in the depressive psychosis group exhibited lower scores than males. There was a 
significant effect of diagnosis on premorbid IQ (F=3.912, df=2, 129, p=0.022) but no significant 
effect of gender (F=1.171, df=1, 129 p=0.281), or gender by diagnosis interaction (F=0.674, 
df=5,134, p=0.511).  
 
4.3.3 Neuropsychological performance 
Figure 4.2 presents neuropsychological test performance in males and females for each of the 
three diagnostic groups.   
 
- 67 - 
 
Figure 4.2 Effect size of impairment in neuropsychological functioning in males (blue bars) and females (red bars) according to diagnostic groups:  
schizophrenia (N=45 males, N=25 females); bipolar/manic (N=14 males, N=20 females), and depressive psychosis (N=15 males, N=21 females) Note:  
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4.3.3.1 Comparison to controls 
Males and females were compared to controls on each neuropsychological domain using ANOVA 
models. The significance level was adjusted for multiple testing by Bonferroni correction and was 
conservatively set at p≤0.008 (0.05/6). In the schizophrenia group, females performed 
significantly worse than healthy controls on learning, attention, executive function and language 
domains whereas males performed significantly worse on all domains.  In the bipolar/manic 
group, females performed significantly worse than healthy controls on neuropsychological 
domains assessing language and learning, whereas males performance was similar to that of 
controls. In the depressive psychosis group females performed significantly worse than controls 
on all neuropsychological domains. There were no significant differences between males and 
healthy controls. 
 
4.3.3.2 Comparison of males and females within diagnostic groups 
A repeated-measures ANOVA of gender, diagnosis and neuropsychological domain showed a 
significant effect of gender (F=5.08, df=1, 112, p=0.026) and of diagnostic group (F=4.342, df=2, 
112, p=0.001), but no significant gender by diagnosis interaction (F=1.458, df=2, 112, p=0.237). 
However, there was a significant three-way interaction between gender, diagnosis and 
neuropsychological domain (F=2.123, df=10, 112, p=0.021), indicating that the profile of 
neuropsychological impairment varies as a function of both diagnosis and sex. To further examine 
the three way interaction in detail, separate analyses for each diagnostic group were repeated. In 
the schizophrenia group there was no significant effect of gender (F=0.079, df=1, 55, p=0.78) and 
no significant gender by neuropsychological domain interaction (F=1.904, df=5, 55, p=0.094) 
(Figure 4.2). Differences between males and females in neuropsychological performance were 
small - not greater than 0.3 standard deviation (ES<0.3). Females performed worse than males 
on language, attention and executive function domains and better than males on WAIS-R verbal 
intelligence and visual-spatial domains. In the bipolar/manic group there was no significant gender 
effect (F=1,604, df=1, 25, p=0.217) but there was a significant gender by neuropsychological 
domain interaction (F=2.854, df=5, p=0.018). Females performed worse than males on language, 
executive function, learning and memory, and visual/spatial domains with effect size of difference 
ranging between 0.2 to 1. Post hoc contrasts revealed a significant difference on the language 
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domain (t=2,37, df=25, p=0.026), with females performing worse than males (ES=-1.05). In the 
depressive psychosis group there was a significant effect of gender (F=5.729, df=1, p=0.023) but 
no significant gender by neuropsychological domain interaction (F=1.229, df=5, 32, p=0.298). 
Females performed worse than males on all neuropsychological domains (Figure 4.2) with effect 
sizes of difference ranging from 0.6 to 0.4.  
 
4.3.3.3 Symptom severity and neuropsychological performance 
I examined gender differences in symptom severity in these diagnostic groups (Table 4.2). There 
were no significant gender differences in symptom severity in any diagnostic group, with the 
exception of disorganisation symptoms in schizophrenia where males had more severe symptoms 
than females (p=0.038). I also examined the associations between symptoms severity and 
neuropsychological performance in males and females in each diagnostic group. No consistent 
pattern of association emerged. The overwhelming majority of correlation coefficients were small 
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Table 4.2 Descriptive Statistics for Test of Gender Differences between Neuropsychological Scores and Symptom Dimensions 
 Schizophrenia Bipolar/Manic Depressive Psychosis 
 Males  Females Males Females Males Females 
 (N=45) (N=25) (N=14) (N=20) (N=15) (N=21) 
Symptom Dimensions       
Manic Symptoms 1.6±2.6 1.7±2.8 6.2±3.3 5.6±3.3 3.3±4.1 0.3±0.5 
Depressive Symptoms 1.4±1.7 1.6 ±2.0 1.1±1.6 0.8±1.6 3.1±1.6 3.5±1.5 
Reality Distortion 4.1±2.3 3.8±2.1 2.2±2.6 3.8±1.0 3.0±2.0 3.6±1.7 
Negative Symptoms 2.2±2.2 1.7±2.8 0.4±0.5 1.1±1.8 2.1±1.7 1.9±2.0 
Disorganization 1.3±0.9 0.6±0.7 0.7±1.5 0.3±0.5 0.1±0.3 0.5±0.9 
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4.4 Discussion 
To the best of my knowledge, this is the first population-based epidemiological study of gender 
differences in neuropsychological performance across a range of psychotic disorders. It provides 
new evidence to what is known about the cognitive impairment in psychoses in two important 
ways. First, while both males and females with schizophrenia showed pervasive 
neuropsychological impairments, males with bipolar/manic or psychotic depressive disorders 
showed no significant impairments compared with healthy controls. Second, the investigation 
shows that gender differences in neuropsychological functions are disorder specific. Gender 
differences were evident in psychotic depression but not in schizophrenia. There was also 
evidence of a gender based domain- specific impairment in bipolar/manic disorder. Females 
performed significantly worse than males on the language domain. Gender differences were not 
due to differences in symptom severity.   
 
Both males and females with schizophrenia showed generalized and clinically severe cognitive 
impairments. There were no statistically significant gender differences in neuropsychological 
performance in schizophrenia. Previous studies reported mixed results (Goldstein et al., 1998, 
Hoff et al., 1998, Seidman et al., 1997). Hoff et al (Hoff et al., 1998) studying first episode and 
chronic schizophrenia patients reported that after controlling for symptom severity there were no 
sex differences in cognition between male and female patients with schizophrenia. Other studies 
reported domain-specific gender differences with males showing greater impairments than 
females in sustained attention, language, executive function and intelligence (Goldstein et al., 
1998, Haas et al., 1991, Kopala and Clark, 1990, Seidman et al., 1997). The results of this 
investigation indicate that the well replicated finding of a severe cognitive impairment in 
schizophrenia is equivalent in males and females at least at onset (Dickinson et al., 2004, 
Knowles et al., 2010, Reichenberg and Harvey, 2007).  
 
In the bipolar/manic group, males showed no cognitive impairments. Gender differences were 
evident in the language domain, where females performed statistically significantly worse than 
males. The impairment in the language domain was very large (more than 1SD compared to 
controls). Whereas, Barret et al., (Barrett et al., 2008) and Carrus et al (Carrus et al., 2010) found 
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that males underperformed females on immediate memory and spatial working memory tasks, I 
saw no evidence for gender differences on related neuropsychological domains. The studies by 
Barret et al., (2008) and Carrus et al., (2010) however, used clinical, not epidemiological samples 
and studied older, and more severe patient samples.  
 
I am not familiar with other studies examining gender differences in neuropsychological 
functioning in patients suffering from depressive psychosis. My data showed distinct cognitive 
patterns in this patient population. Females were impaired across all neuropsychological domains 
compared to males. Males showed relatively preserved cognitive ability.  
 
One possible explanation for my finding could be female-specific vulnerability to the effects of 
psychotic illness and medication. Antipsychotic medications have been shown to adversely effect 
cognition (Arnsten et al., 1994). However, severity of neuropsychological impairments in females 
was not identical across domain and disorders. Therefore a complex interaction of medication and 
vulnerability would be required in order to support this explanation. Alternatively, the tentative 
nature of diagnosis on first presentation may help explain some of the findings. Patients were 
assessed 6 months after their first admission. Previous research has shown that while a 
schizophrenia diagnosis is reasonably stable, 20% of bipolar and 30% of major depression will 
shift diagnosis to schizophrenia spectrum within 24 months of their first admission (Longenecker 
et al., 2010, Schwartz et al., 2000). One could speculate that if such a diagnostic shift was more 
likely to be found in female patients it could help explain the findings.  
 
This investigation has several strengths. It is a large, first-episode psychosis study incorporating a 
population-based epidemiological sample. A limitation of most previous studies is that they used 
clinical rather than epidemiological samples. Clinical samples involve patient series, not complete 
populations. As a result, it is difficult to generalize from studies using clinical samples. The fact 
that a large healthy comparison group was included also strengthens the interpretation of my 
results. However, the following limitation of this investigation should also be acknowledged. I had 
insufficient information on medication to reliably determine dosage, and no patients were drug 
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naive. Medication type and side effects can influence subjects' neuropsychological performance. 
Nevertheless, I observed only weak correlations between neuropsychological functioning and 
symptom severity.  
 
In summary, the results of this investigation indicate that early in the course of psychotic illness, 
gender related factors appear to moderate the severity of cognitive deficits in bipolar/mania and 
depressive psychosis patients. In contrast, gender related factors have only minimal effects on 
the neuropsychological impairment in schizophrenia. Such knowledge may be valuable in 
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Chapter 5 The course of neuropsychological impairment over 
the first decade of illness 
5.1 Introduction 
The longitudinal course of the cognitive dysfunction in psychoses has yet to be fully clarified. 
Whereas some studies in chronic institutionalized patients have revealed a progressive decline in 
cognitive abilities, studies of first episode patients have indicated that initial cognitive deficits 
might remain stable over time. Applying a longitudinal design studies have explored the trajectory 
of cognitive dysfunction in first episode psychosis. However, follow-up studies are complex to 
carry out, expensive, very demanding and time consuming for both researchers and participants. 
Neuropsychological tests, in particular, can be difficult to complete by psychotic patients purely 
due to lack of motivation or failure to understand tasks, or not remembering the instructions 
(Barnett et al., 2010). Also, issue of attrition can have a negative effect on prospective longitudinal 
studies of cognition (Keefe and Harvey, 2008, Kurtz et al., 2005). In other words, attrition occurs 
in instances where participants drop out of the study or it is impossible to trace them. As a result, 
a number of participants diminish in the follow up part which consequently affects the 
generalisability and possible bias of the findings (Menard, 2002). 
 
5.1.1 Longitudinal studies of neuropsychological profile in first episode 
psychosis: review of the literature 
The natural course of cognitive dysfunction remains under debate. Whether cognitive dysfunction 
is stable, declines or even improves over time or whether there is time-related variability in deficit 
profiles is still unclear. Four hypotheses put forward to describe the course of the cognitive 
impairment in schizophrenia are illustrated in Figure 5.1. The static deficit hypothesis (Hoff et al., 
1999, Leeson et al., 2009a, Leeson et al., 2009b, Nopoulos et al., 1994, Rund, 1998, Rund et al., 
2007, Sweeney et al., 1991) predicts static cognitive impairment, manifested as deficits that are 
evident during or soon after the first episode and remain stable. The deterioration hypothesis (Oie 
et al., 2008) predicts decline in cognitive performance following the first episode. The amelioration 
hypothesis suggests improvement over time in cognitive performance (Addington et al., 2005, 
Gold et al., 1999, Hoff et al., 1991, Rodriguez-Sanchez et al., 2008, Scottish Schizophrenia 
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Research Group, 1988). Finally, the lag hypothesis (Hoff et al., 1999) predicts growth in cognitive 
abilities, but growth that lags behind the more rapid growth in healthy individuals. 
 
Figure 5.1 Schematic representation of four hypotheses of the course of cognitive functioning in 
schizophrenia
 
(The blue line represents healthy comparison subjects and the red line represents 









The very first longitudinal study was reported by Moran et al., in 1960 (Moran et al., 1960). The 
authors studied a sample of 55 not medicated paranoid schizophrenic patients using a word 
meaning measure and then followed them up 6 years later (N=30). Moran et al., (1960) (Moran et 
al., 1960) reported remarkable stability over time but a slight decline found in performance on 
definitions. This was explained by normal aging process rather than with increased schizophrenic 
pathology or length of hospitalization. A methodological strength in this study was that the 
patients were probably not medicated (Moran et al., 1952). In more recent years, there have been 
an increasing number of longitudinal studies of first episode psychosis. Summary of the 
neuropsychological results of all such known studies in chronological order of publication date is 
presented in Table 5.1. Like the review of Rund (Rund, 1998), Hoff et al., (Hoff et al., 2005) and 
Bozikas & Andreou (Bozikas and Andreou, 2011) studies indicate either an improvement in 
cognitive function or stability of functions in the first several years of illness. 
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Close inspection of Table 5.1 indicates that the majority of longitudinal studies of the course of 
neuropsychological functioning had a follow-up time of only 1– 4/5 years (Addington et al., 2005, 
Albus et al., 2006, Albus et al., 2002, Bilder et al., 1991, Censits et al., 1997, de Mello Ayres et 
al., 2010, Hill et al., 2004, Hoff et al., 1991, Hoff et al., 2005, Leeson et al., 2009b, Mayoral et al., 
2008, Nopoulos et al., 1994, Rodriguez-Sanchez et al., 2008, Rund et al., 2007, Scottish 
Schizophrenia Research Group, 1988, Sweeney et al., 1991, Zipparo et al., 2008). Only five 
studies had a follow-up time of more than 4/5 years of illness (Gold et al., 1999, Hoff et al., 1999, 
Leeson et al., 2009a) with three studies reporting a follow-up of ten years or more (Hoff et al., 
2005, Oie et al., 2008, Stirling et al., 2003). 
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Table 5.1 Review of longitudinal neuropsychological studies of first episode (FE) psychotic patients with a length of follow-up of one or more year. 
Study Subjects Follow-up (years) Findings 
Scottish Sz Research 
Group (1988) 
49 FE schizophrenia 1 Improvement on Ravens Progressive Matrices, block design, and digit copy;  
unchanged in vocabulary and similarities 
Hoff et al., (1991) 15 FE schizophrenia  2 Improvement on executive, concentration/speed, and global scales 
 
Bilder et al., (1991) 28 FE schizophrenia 1 High stability in neuropsychological deficit. Improvement on most functional 
domains (attention, memory, motor functions). Decline on attentional span (digit 
span) 
Sweeney et al., (1991) 15 FE schizophrenia 
24 chronic patients 
1 High stability on memory, verbal fluency, verbal learning/recall, visual 
memories Improvement on verbal recognition memory, orientation, 
psychomotor skills (Trails A and B, digit symbol, finger tapping-nondom, line 
orientation, verbal recognition memory on Rey auditory verbal learning test) 
Nopoulos et al., (1994) 35 FE schizophrenia 
 
1 - 2 High stability. Improvement on complex attention and executive function 
Censits et al., (1997) 30 FE schizophrenia 
30 previously treated 
1.58 (19 months) High stability (no decline) There were no differences in neuropsychological 
performance over time between first-episode and previously treated patients. 
Hoff et al., (1999) 42 FE schizophrenia 
16 normal controls 
4 - 5 High stability. Patients did not improve as much as controls on verbal memory 
and sensory-perceptual functions 
Gold et al., (1999) 21 FE schizophrenia 
33 recent onset 
schizophrenia 
5 Improvement on performance and Full Scale IQ, letter cancellation, logical 
memory-immediate, WCST categories, decline in dominant and non-dominant 
finger tapping 
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Table 5.1 (continued) 
Study Subjects Follow-up (years) Findings 
Albus et al., (2002) 50 FE schizophrenia 
50 normal controls 
2 Stability of cognitive domains in patients over time except of  improvement on 
verbal memory scale and absence of improvement on visual memory; visual-
motor processing/attention and abstraction/flexibility did not change 
Stirling et al., (2003) 24 FE schizophrenia 10 -12 High stability on measures of executive/frontal function. Decline on object 
assembly, picture completion, and memory for designs. 
Hill et al., (2004) 45 FE schizophrenia 
33 normal controls 
1 - 2 
 
Stability in verbal memory and other functions through 2 year period 
Hoff et al., (2005) 21 FE patients  
(13 schizophrenia; 
6 schizoaffective; 
 2 recovered 
(asymptomatic)) 
8 controls 
10 Improved performance (patients and controls as a group) in verbal intellectual 
functioning, the Stroop Color–Word test, and motor speed. Patients actually 
improved more than controls on a measure of immediate visual memory. 
Relative stability through at least 10 years of illness. 
Addington et al., (2005) 105 FE psychosis (all 
time point) 
66 controls (1 year) 





 year –  patients failed to improve on  verbal fluency, visual memory, 
visuomotor sequencing and the Stroop, whereas controls failed to improve on 
auditory verbal learning, WCST and psychomotor speed 
Albus et al., (2006) 71 FE schizophrenia 
71 controls 
2 - 5 Improvement in both groups over time in the majority of subtests. Slight 
deterioration in verbal fluency in patients 
Rund et al., (2007) 138 FE psychosis (at 
1 year follow-up) 
111 FE psychosis (at 
2 year follow-up) 
1 - 2 High stability or slight improvement on most of neurocognitive domains (with 
the most significant improvement during the first year). 
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Table 5.1 (continued) 
Study Subjects Follow-up (years) Findings 
Rodríguez-Sánchez et al., 
(2008) 
112 FE schizophrenia 
22 controls 
1 Improvement in cognitive performance in virtually all the cognitive domains 
after one year. However, patients continued to show marked cognitive deficits 
after one year, unlike healthy volunteers. The longitudinal cognitive changes 
were similar in patients and controls in all domains except verbal memory 
Øie et al., (2008) 15 FE schizophrenia 13 Decline in neuropsychological performance particularly in verbal memory, 
attention, and processing speed. 
Mayoral et al., (2008) 24 FE psychosis 
29 controls 
2 Improvement in almost all cognitive domains. However, this improvement 
disappeared in the patient group after controlling for improvement in 
symptomatology 
Zipparo et al., (2008) 32 FE schizophrenia 2 - 3 Overall improvement in cognitive functioning over the follow-up interval, they 
also exhibited a slight (non-significant) decline in verbal learning and memory 
over the same period 
Leeson et al., (2009) 60 FE schizophrenia 
27 controls 
1 - 3 Patients with preserved IQ or deteriorated IQ at baseline showed similar IQ 
improvement as controls whereas patients with low IQ at baseline showed less 
improvement. Similar changes in memory and executive function in patients and 
controls 
Leeson et al., (2009) 104 FE schizophrenia 
25 controls 
31 FE schizophrenia 
25 controls 
1 - 3 
 
6 
Stability in measures of learning from feedback over 3 and 6 years. However, 
patient self-shifting performance over the first year was inconsistent 
de Mello Ayres et al., 
(2010) 
56 FE psychosis 
70 controls 
1 - 2.5 Improvement in schizophrenia, affective psychoses, and control subjects, with 
no significant group-by-time interactions 
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5.1.2 Studies without a healthy control group 
Virtually all studies that do not include a control group report stability or improvement in all 
neuropsychological domains for intervals of 1 to 4 years. The only exception is a study by Gold et 
al., (Gold et al., 1999), whose patients worsened over time in motor speed (finger tapping). 
However, improvement over 5 years in intellectual abilities in patients with first episode psychosis 
reported by Gold et al., (Gold et al., 1999) was attributed to neuroleptic treatment. Moreover, Gold 
(Gold, 2004) stated in his review that course of impairment in schizophrenia “is a stable, not a 
moving target” and relatively independent from symptoms. 
 
Regarding the evolution of deficits over longer periods of time, two studies that investigated this 
question reported decline in neuropsychological performance. Stirling et al., (Stirling et al., 2003) 
found decline in some tasks of visuospatial ability (object assembly, picture completion, and 
memory for designs) in patients after a mean follow-up period of 10 years. Oie et al., found 
decline in neuropsychological performance particularly in verbal memory, attention, and 
processing speed (Oie et al., 2008). However, studies that do not include a healthy control group, 
although providing important information regarding the absolute time course of cognitive abilities 
in schizophrenia, are not informative regarding changes that might occur compared to healthy 
individuals, and thus do not take into account other factors that might affect performance, such as 
familiarity with the procedures and practice effects, or age-related cognitive changes. This is 
particularly evident in the above-mentioned study by Stirling et al., who did not account for the 
effects of aging in the statistical analyses but utilized comparisons to normative data (Stirling et 
al., 2003). Unfortunately, normative data is frequently based on relatively small samples and 
includes ranges of ages which don‟t allow for an accurate assessment of the effects of age on 
cognitive tests 
 
5.1.3 Studies with the presence of a healthy control group 
In studies that include a healthy control group, cognitive changes in patients for the most part 
parallel those observed in healthy control subjects. However, in some studies patients failed to 
improve as much as controls, or even deteriorated in some of the tasks used to assess 
performance. Studies investigating the course of neuropsychological deficits in first  episode 
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patients relative to a healthy control groups differ along several dimensions, thus limiting the 
interpretability of results: For example, there are important differences among studies in patient 
sampling, with some studies (Albus et al., 2002, Bilder et al., 1991, Censits et al., 1997) 
assessing only patients with schizophrenia, while others include patients with schizoaffective, 
schizophreniform and other psychotic disorders (Addington et al., 2005, Hill et al., 2004, Hoff et 
al., 1999, Hoff et al., 2005, Leeson et al., 2009a, Leeson et al., 2009b, Rodriguez-Sanchez et al., 
2008) or even patients with affective disorders with mood-incongruent delusions (Mayoral et al., 
2008). Other important methodological differences include: (1) patient recruitment strategies 
(inpatients versus inpatients and outpatients and the timing of baseline neuropsychological 
evaluation in patients (before initiation of treatment versus variable time into stabilization of 
symptoms, (2) duration of follow-up period from 1 to 13 years, as well as (3) differences in the 
specific neuropsychological measures implemented, their categorization, and their use in 
statistical analyses. For example, Mayoral et al., included measures of verbal fluency in their 
composite measure of executive function, whereas most other studies assess verbal fluency 
separately (Mayoral et al., 2008) [for example:(Addington et al., 2005, Albus et al., 2006)], or as a 
part of a composite measure of language ability [for example (Censits et al., 1997, Hoff et al., 
1999, Hoff et al., 2005)]. Another potential source for variation in findings is differences in 
recruitment strategies for the healthy control subjects. Finally, an additional confounding factor is 
attrition rate, which ranges widely between studies, from 70 – 90% in some studies (Albus et al., 
2006, Albus et al., 2002, Hill et al., 2004, Mayoral et al., 2008, Rodriguez-Sanchez et al., 2008) to 
less than 50% in others (Addington et al., 2005, Hoff et al., 2005). 
 
5.1.4 Studies with first episode, early onset and chronic patients 
Most studies examining neurocognitive deficits in psychosis have involved chronic patients (Bilder 
et al., 2002, Harvey et al., 1997, Mohamed et al., 1999, Nuechterlein, 1985) and the results may 
reflect the long-term illness and/or exposure to treatment. Overall severity of the deficit is about 
0.3 to1.0 standard deviations greater in the groups of chronic patients compared to first-episode 
patients (Bilder et al., 1992, Hoff et al., 1998). It remains unclear whether this discrepancy reflects 
sampling bias (i.e., many first-episode patients will not go on to have chronic illness) or a 
deteriorating course and associated cognitive decline in some patients.  
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Longitudinal studies of first onset of psychosis patients are of special relevance when it comes to 
evaluating the course of cognition in schizophrenia since they provide an adequate and realistic 
baseline measure of cognitive performance. Most of the previous studies in first onset of 
schizophrenia have described stability or improvement in cognitive functioning over time (Censits 
et al., 1997, Gold et al., 1999, Hill et al., 2004, Hoff et al., 1999, Hoff et al., 2005, Nopoulos et al., 
1994, Sweeney et al., 1991). In contrast, Stirling et al. (Stirling et al., 2003) and Øie et al., (Oie et 
al., 2008) reported a progressive cognitive deterioration. Nevertheless, follow-up investigations of 
cognition in chronic schizophrenia have shown a marked deterioration over time (Harvey et al., 
1999b, Morrison et al., 2006, Waddington and Youssef, 1996). Some of the cross sectional 
studies, but not all (Goldberg et al., 1993, Hyde et al., 1994) have also suggested that the 
duration of illness was positively associated with greater cognitive deficits, thus supporting the 
notion of a progressive cognitive decline in schizophrenia (Bilder et al., 1992, Heaton et al., 1994). 
However, Rund in a review of the literature, concluded that there is no significant progressive 
cognitive impairment in schizophrenia (Rund, 1998).  
 
Several methodological limitations (small sample size, lack of cognitive longitudinal assessments 
in the control group, previously treated patients) might contribute to inconsistent results. Kurtz et 
al., update on neurocognitive impairments across the lifespan in schizophrenia revealed that in 
outpatient groups (age range from 20-65 years) overall cognitive dysfunctions remain stable and 
no further deterioration was present. In particular, full scale IQ, attention, memory, verbal and 
visual skills remained remarkably stable over time (Kurtz et al., 2005). The existence of 
longitudinal comparison samples of healthy volunteers is of special relevance when considering 
the effects of repeated exposure to cognitive tests (practice effect) and thus interpreting the 
results of longitudinal investigations. Cervellione et al., followed a sample of 26 early onset 
schizophrenia and 26 healthy controls 13 months after baseline assessment (Cervellione et al., 
2007). Statistics from this study have shown relatively stable course of cognitive dysfunctions 
despite changes in clinical status. Frangou et al., examined cognitive function over a mean 
interval of 4 years in 20 adolescents with schizophrenia (Frangou et al., 2008). They found that 
most aspects of cognitive function remain relatively stable in early onset schizophrenia patients 
during adolescence; there was evidence for deterioration in immediate verbal memory and 
attention while speed of information processing show improvement. 
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The existing literature does not provide an adequate answer to the question of the course of 
cognitive impairment in psychosis. The majority of studies suggest that neuropsychological 
deficits that are present following a first episode of psychosis remain stable over time (Bozikas 
and Andreou, 2011, Hoff et al., 1999, Hoff et al., 2005, Leeson et al., 2009a, Leeson et al., 2009b, 
Nopoulos et al., 1994, Rund, 1998, Sweeney et al., 1991). These findings support the view of 
schizophrenia as a static encephalopathy. In this view schizophrenia is associated with 
neuropsychological impairment that begins at the time of or even before onset of 
psychopathological symptoms and remains stable over time even during symptom free periods 
(Bozikas and Andreou, 2011, Hoff et al., 1999, Leeson et al., 2009a, Leeson et al., 2009b, 
Nopoulos et al., 1994, Rund, 1998, Rund et al., 2007, Sweeney et al., 1991). 
 
Nevertheless, other studies provide support for the view of schizophrenia as a degenerative 
neuropsychiatric disorder. This is characterised by onset in young adulthood followed by a length 
period of gradual cognitive decline. This view is supported by studies using MRI (Mathalon et al., 
2001), in studies including patients with late-life schizophrenia (Fucetola et al., 2000, Harvey et 
al., 1999a, Harvey et al., 1999b), as well as in studies showing changes over time in specific 
cognitive functions [e.g., (Bilder et al., 1991).] 
 
This evidence on stability in neuropsychological performance is consistent with Kurtz (Kurtz et al., 
2005) investigation on neurocognitive impairments across the lifespan in schizophrenia. The 
study revealed that in outpatients group (age range from 20-65years) overall cognitive 
dysfunctions remain stable and no further deterioration is present. In particular, full scale IQ, 
attention, memory, verbal and visual skills remained remarkably stable over time. With regards to 
other psychosis group, Pavuluri et al, reported that cognitive trajectory is stable over time in 
children diagnosed with bipolar disorder (Pavuluri et al., 2009). Research yelled that adults and 
older adults also show stable course of cognition over 1-3 year interval (Depp et al., 2008, Mur et 
al., 2008). Yet, no evidence for decline in bipolar patients has been published. Further to cognitive 
stabilization, Heaton et al., published one of the first largest multi-year follow-up study including a 
large sample of 142 schizophrenia outpatients and 206 controls (Heaton et al., 2001). He reported 
no decline after 5 years interval. No significant differences in neuropsychological
 
change were 
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found between schizophrenic subgroups defined by
 
current age, age at onset of illness, baseline 
level of neuropsychological impairment,
 
improvement or worsening of clinical symptoms, and 
occurrence of
 
incident tardive dyskinesia. Norms for change also failed to
 
show 
neuropsychological progression in individuals with schizophrenia.
 
Heaton (Heaton et al., 2001) 
also pointed out that neuropsychological impairment in ambulatory
 
persons with schizophrenia 
appears to remain stable, regardless
 
of baseline characteristics and changes in clinical state.  
 
The main outcome of the literature review is that cognitive deficits are relatively stable over long 
periods after onset of schizophrenia. If any change occurs, it is more often an improvement in 
neuropsychological performance. Some neuropsychological functions were reported to improve in 
first episode patients during the first stage of illness (Hoff et al., 1992, Nopoulos et al., 1994, 
Sweeney et al., 1991). Furthermore, Szoke et al., carried out a meta-analysis of 53 longitudinal 
studies of cognitive performance in schizophrenia (Szoke et al., 2008). Results indicated a 
significant improvement in most cognitive domains in the course of antipsychotic treatment. 
However this was attributed to practice-effects. Also, stability in performance on semantic verbal 
fluency in both schizophrenic and healthy controls was observed. Szoke et al., proposed that 
semantic verbal fluency (category) may be a possible cognitive endophenotype in schizophrenia 
disorder (Szoke et al., 2008). In other words, verbal fluency impairment is suggested to be a 
hereditable state-dependant characteristic of schizophrenia disorder (a genetic biomarker of 
schizophrenia). This is in line with a number of studies that reported high level of verbal fluency 
deficit in both schizophrenia patients and first-degree relatives of those patients (Snitz et al., 
2006, Szoke et al., 2008). 
 
5.1.4 Aims and objectives 
The aim of this section of the thesis is to characterize the trajectory of cognitive functioning along 
the course of the psychotic illness. We examined the following three questions:  
4) What is the trajectory of the cognitive impairment seen in psychosis after the first 
psychotic episode?  
5) Do all neuropsychological deficits follow the same trajectory?  
6) Do different psychotic disorders present the same trajectory of cognitive functioning?  
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5.2 Materials and methods 
5.2.1 Follow-up study cohort  
The mean time of follow-up was 104.2 months (SD=28.84) for patients (N=108) and 102.32 
(SD=30.03) for the comparison group (N=103). Fifty five subjects in the follow-up sample of 108 
patients met ICD-10 (1992) diagnostic criteria for schizophrenia, and an additional nine met ICD-
10 diagnostic criteria for schizoaffective disorder. Nineteen met diagnostic criteria for 
bipolar/manic, fourteen for depressive psychosis and eleven for other psychosis.  
 
5.2.1.1 Cases 
When recruited to the baseline study, participants provided detailed contact details for 
themselves, their GP‟s and their relatives, and gave consent to be contacted for follow-up. At time 
of follow-up, we wrote to all participants, inviting them to take part in this follow-up study, or made 
contact with them via a care co-ordinator, if in contact with services. A reply slip was enclosed, for 
participants to indicate whether or not they would take part, or require further information. Those 
from whom no reply was received were called by telephone in order to make initial contact, and 
thereafter non-responders were sent 2 further invitations at one-month intervals. Where it was not 
been possible to obtain a telephone number for the participant, we would call at their address, if 
they had not contacted us after 2 weeks. A minority had moved residence in the intervening 
years, and those participants were traced through contact with their GP/consultant psychiatrist or, 
if necessary, via the relevant Primary Care Trust. For difficult-to-trace participants or for death 
certificates of those who died during the follow-up period, both the National Strategic Tracing 
Service Website (https://nww.nsts.nhsia.nhs.uk) and the Office of National Statistic (ONS) were 
applied to in order to trace participant. 
 
Clinical evaluation and diagnosis 
At follow-up, clinical information were obtained through various sources: participant interview, 
casenote review and informant interview. The casenote review involved a detailed review of the 
medical and nursing case records of all the cases (both interviewed and non-interviewed) to 
supplement information obtained at interview. Information derived from several sources was 
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deemed to be superior to that from only one source. Instances in which patient interview was 
achieved are hereafter referred to as „patient interview‟ instances in which interviews were 
possible with neither the participant nor an informant are denoted „casenotes only‟. 
 
Information on illness course was obtained using an amended version of the WHO Life Chart 
(World Health Organization., 1994). This measure has been used successfully in previous long-
term follow-up studies, and has been shown to be reliable in the assessment of clinical ratings 
(Susser et al., 2000). Presence or absence of psychotic symptoms during the follow-up period 
was established with the SCAN (World Health Organization., 1994), in accordance with the WHO 
and other long-term outcome studies (Jablensky et al., 1992). In addition, the Positive and 
Negative Syndrome Scale (Kay et al., 1989) and the Scale for the Assessment of Negative 
Symptoms (SANS) (Andreasen, 1982) were used to assess presence and severity of current 
positive and negative symptoms of psychosis.  
 
For each participant a lifetime diagnosis according to ICD-10 (World Health Organisation, 1992) 
and DSM-IV (American Psychiatric Association, 2000) criteria was formulated in consensus 
meetings with senior clinicians and academics where information from all the sources described 
above were considered and reviewed, blind to subject age, ethnicity, treatment, and baseline 
diagnosis. These diagnoses were used for the present analysis. 
 
5.2.1.2 Healthy controls 
When recruited originally during the AESOP study, participants provided contact details for 
themselves. We wrote to all healthy volunteers, inviting them to take part in this follow-up study. A 
reply slip was enclosed, for participants to indicate whether or not they would take part, or require 
further information. If no reply to this was received after 2 weeks, then letters were followed up, 
wherever possible, with a telephone call until initial contact was established. Where it had not 
been possible to obtain a telephone number for the participant, we would call at their address 
(including morning, afternoon or evening visit) if they had not contacted us after 4 weeks.  
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The derivation of the follow-up sample included in the analysis reported here is presented in 
Figure 5.2 The analytic follow-up cohort comprised of 108 patients and 103 controls. 
 
Figure 5.2 The analytic cohort – follow-up study 
AESOP Follow-up Cohort 
                 Cases Controls 
Eligible  592 412  
Non-Participants (refused or could not be 
contacted or spoke no English) 
 
202 
   
Consented  390 412  




   
148 
Complete Neuropsychological Testing   245 264  
Excluded:    
 Poor English speakers – Likely to affect 
neuropsychological tests 
 Missing data on more than three 
neuropsychological measures 
 Diagnosis of schizoaffective disorder – Too 








Remaining in Analytic Cohort at baseline  187 177  
Lost to follow-up: 















Cohort at the follow-up   108 103  
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5.2.2 Neuropsychological assessment 
All participants underwent a battery of neuropsychological tests assessing general intellectual 
ability (IQ) as well as additional specific cognitive domains: (1) Learning and Memory (verbal and 
visual); (2) Executive functions and working memory; (3) Attention, concentration and mental 
speed; (4) Language; and (5) Visual constructual/perceptual abilities. 
 
Full-scale IQ was derived from the WAIS-R (Wechsler, 1981) subtests Vocabulary, 
Comprehension, Digit Symbol Coding and Block Design. Verbal and Performance IQ were 
computed based on the relevant sub tests. Scoring followed standard procedures. Premorbid 
intelligence was estimated using the National Adult Reading Test (NART) (Nelson and Willison, 
1991). 
 
Specific cognitive domains were assessed using the following tests:  
 
1. Learning and memory:  verbal ( short-term verbal immediate recall and delayed verbal 
recall) were assessed using trials 1–5, 6 and 7, respectively, of the Rey Auditory Verbal 
Learning Test (RAVLT) and  visual (immediate and delayed recall) was examined using 
Visual Reproduction of the Wechsler Memory Scale - Revised (WMS-R) (Wechsler, 
1987). 
2. Executive functions and working memory  were evaluated using the Trail Making Test 
- part B, Letter-Number Span, and Sets AB and B of Raven‟s Coloured Progressive 
Matrices (CPM) 
3. Attention, concentration and mental speed were measured using Trail Making - part A 
and the WAIS-R Digit Symbol subtest.  
4. Language was evaluated using the Semantic Fluency (categories „body parts‟, „fruits‟ and 
„animals‟), and Letter Fluency (letters F, A, S). 
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5. Visual-construction/perceptual abilities were assessed using set A of Raven‟s 
Coloured Progressive Matrices. 
 
(Full description; please see chapter 3.2.4 Neuropsychological assessment). 
 
5.2.3 Statistical analysis 
Demographic and clinical characteristics of the baseline and follow up subgroups were compared 
using t-test and chi-square tests. Generalized Linear Mixed-Model Regression models were used 
to test the deterioration, static, lag and improvement hypotheses. Generalized Linear Mixed-
Model Regression allows to maximise the use of the longitudinal nature of our data, as this 
technique permits the inclusion of multiple measurements per person, and irregular intervals 
between measurements, thereby increasing statistical power while controlling for within-individual 
variation. The effects of interest in the Generalized Linear Mixed-Model were the group main 
effect and the interaction between group and age (time). Age (time) was included as a main effect 
in all models but was not the effect of interest. Splines were used to model age effects (i.e., time) 
on cognition. A spline model estimates the response relation without assuming that the data 
follow a particular form, such as linear or cubic. This allows for an evaluation of the functional 
form of associations, and characterization of risk pattern including points of non-linearity 
(threshold effects). Ethnicity, years of education and gender were used as confounders in all 
models. Our primary analysis focused on general intellectual ability (IQ). Significance level was 
set at p=0.05 (two-sided). All analyses were done using SAS version 9.3.  
 
The static deficit hypothesis predicts static cognitive impairment, which is manifest in early-
emerging cognitive deficits that remain stable. In generalized linear models with splines, this 
course is characterized by statistically significant group differences between cases and controls, 
but no statistically significant group by time interaction. The splines modelling the contrast 
between cases and controls will appear straight or with only minimal curving (Figure 5.1). The 
deterioration hypothesis predicts premorbid decline in cognitive performance. In generalized 
linear models with splines this course is characterized by statistically significant group by time 
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interaction. The spline modelling the contrast between cases and controls is characterized by a 
negative slope, or curving indicating an inverted-J shape (Figure 5.1). The lag and amelioration 
hypotheses predict slower or faster cognitive development relative to controls.  In generalized 
linear models with splines this course is characterized by statistically significant group by time 
interaction. The spline modelling the contrast between cases and controls is characterized by a 
positive slope, or curving indicating J-shape (Figure 5.1). To test these hypotheses, I examined 
the statistical significance of the interaction and the direction of the splines that model the contrast 















- 91 - 
5.3 Results 
5.3.1 Characteristics of cohort 
5.3.1.1 Representativeness 
Table 5.2 shows characteristics of the original cohort at baseline and of the follow up subsample. 
Follow-up neuropsychological evaluations were completed on 108 patients (65 males and 43 
females) who were of 28.24 years old (SD= 9.9) at baseline and 37.38 (SD= 10.38) at follow-up, 
and 103 comparison subjects (45 males and 58 females) who were 35.99 years old (SD=10.87) at 
baseline and 44.57 (SD=11.36) at follow-up. There were no statistically significant differences 
between the subsamples of patients and controls that were followed-up and the original baseline 
cohorts in age [patients t(293)=1.13, p=0.258; controls t(277)=0.82, p=0.408], gender [patients 

2
(1) =1.06, p=0.303; controls 
2
(1)=0.00, p=0.992], premorbid intellectual functioning [patients 
t(293)=0.11, p=0.908; controls t(277)=-1.64, p=0.102] and current IQ score [patients t(293)=0.46, 
p=0.647; controls t(277)=-1.68, p=0.093]. There were statistically significant differences between 
the subsamples of controls and the baseline cohort in ethnicity [
2
(1) =15.64, p=0.001] and in 
years of education [
2
(2) = 12.45, p=0.002] but not in the subsamples of patients [ethnicity: 
2
(1) 
=0.00, p=0.994; patients years of education: 
2
(2) =2.32, p=0.314]. Overall, the patients from the 
original cohort at baseline were similar to those in the follow up in terms of the demographic 
variables. This similarity suggests that the follow up cohort is a representative sample of the 
original cohort at baseline. 
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(N = 108) 
Controls 
(N = 103) 
    Mean          SD   Mean        SD     Mean        SD    Mean        SD   Mean          SD   Mean         SD 
Age    29.64          10.41   37.24        12.87     28.24         9.90    35.99        10.87    37.38         10.38    44.57       11.36 
      N              %     N            %      N            %      N            %   
Gender  (Male)    101             54.0     77          43.8     65             60.2      45            43.7 -- -- 
Ethnicity  (White)    109             59.0   113          64.4     63             58.9      41            39.8 -- -- 
Years of Education                
11 (compulsory)    123             64.4     84           47.7      66             62.0      38           36.9  -- -- 
12-13(post-compulsory)      40             21.5     52           29.5        21             19.0      21           20.4 -- -- 
14 or more (college, graduate or post-
graduate) 
     24             14.1     40           22.8       21             19.0       44           42.7 -- -- 
    Mean          SD   Mean        SD     Mean        SD    Mean        SD   Mean          SD   Mean         SD 
Estimated premorbid IQ     99.36         13.24    106.3         12.63      99.17       14.54    108.85      12.39   102.10       15.12   107.52      15.73 
Current IQ     92.40         16.59    102.93       15.15      91.46       17.58    106.19      16.43     89.75       16.31   105.91      15.23 
Patients: age t (293) =1.13, p=0.258; Controls age: t (277) =0.82, p=0.408 
Patients gender: chi-square (1) =1.06, p=0.303; Controls gender: chi-square (1) =0.00, p=0.992 
Patients ethnicity: chi-square (1) =0.00, p=0.994; Controls ethnicity: chi-square (1) =15.64, p=0.001 
Patients years of education: chi-square (2) =2.32, p=0.314; Controls years of education: chi-square (2) = 12.45, p=0.002 
Patients: premorbid IQ t (293) =0.11, p=0.908; Controls premorbid IQ: t (277) =-1.64, p=0.102 
Patients: current IQ t (293) =0.46, p=0.647; Controls current IQ: t (277) =-1.68, p=0.093 
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5.3.2 General intellectual ability 
Deterioration hypothesis 
There was evidence for cognitive deterioration among schizophrenia and bipolar/mania patients 
(Figure 5.3 and Figure 5.5). Examination of the splines demonstrated that schizophrenia and 
bipolar/mania patients had worsening performance on full scale IQ, and in particular on verbal IQ 
over time (p=0.02 and p=0.014 for time by group interaction for schizophrenia and bipolar/mania, 
respectively). Deterioration began in late adolescence and continued progressively until the 4
th
 
decade of life, after which performance levelled off with an impairment of approximately 1 SD.  
 
Static hypothesis 
Schizophrenia and bipolar/mania patients exhibited static cognitive deficits on performance IQ 
(Figure 5.4). A similar pattern was also apparent among patients with depressive psychosis. 
Analyses showed that these groups had lower scores than healthy comparison controls but the 
difference between patients and controls did not change over time, indicating that their 
impairment in performance IQ emerged by late adolescence and remained steady throughout 
adult life.  
 
Lag and amelioration hypotheses 
None of the groups showed a course consistent with the characteristics of the lag or amelioration 
hypotheses.  
 
5.3.3 Specific cognitive functions 
Deterioration hypothesis 
There was evidence supporting cognitive deterioration among schizophrenia patients on 
neuropsychological measures assessing specific processes of memory (Immediate Recall) and 
reasoning (Raven‟s Coloured Progressive Matrices set AB) (Figure 5.9). Deterioration on the 
Raven‟s Coloured Progressive Matrices set AB began later in life. Cognitive deterioration was 
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also evident on the category fluency and Trails Making Test Part A, with a similar pattern of 
deterioration later in life. These effects were only significant at trend level (p=0.067 and p=0.074, 
respectively) (Figure 5.8 and 5.7). Deterioration on specific memory processes was also evident 
in bipolar/mania patients (Figure 5.6), and in patients with other psychoses (Figure 5.6). There 
was evidence for deterioration of bipolar/mania patients in verbal learning (Figure 5.6), yet the 
group x time interaction was not statistically significant (p=0.081). In patients with other psychoses 
deterioration began later in life (Figure 5.6) (p=0.007 for verbal learning, p=0.10 for immediate 
recall, p=0.0075 for delayed recall, p=0.088 for visual memory).  
 
Static hypothesis 
Static deficits were the dominant course evident in schizophrenia on specific cognitive functions, 
and were observed for verbal learning and delayed recall (Figure 5.6), digit symbol coding 
(Figure 5.7), letter fluency (Figure 5.8), Trail Making Test Part B, Letter-Number Span (Figure 
5.9), and Raven‟s Coloured Progressive Matrices set A and set B (Figure 5.10 and 5.9). Static 
deficits were observed in bipolar/mania for Trail Making Test Part A, digit symbol coding (Figure 
5.7), category fluency (Figure 5.8) and Raven‟s Coloured Progressive Matrices set A (Figure 
5.10). Static deficits were observed in depressive psychosis for Trail Making Test Part A (Figure 
5.7), Trail Making Test Part B, and Letter-Number Span (Figure 5.9). 
 
Lag and amelioration hypotheses 
A frequent course in the depressive psychosis group was of later-life amelioration. Deficits 




 decades of life but performance improved thereafter. This was observed 
for verbal learning, immediate recall, delayed recall (Figure 5.5), digit symbol coding (Figure 5.7), 
letter fluency (Figure 5.8), and Raven‟s Coloured Progressive Matrices set B (Figure 5.9). The 
other psychoses group demonstrated a course characterized by amelioration on the Trail Making 
Test Part A (Figure 5.7). 
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Figure 5.3 IQ scores by age in healthy comparison subjects and patients with 
schizophrenia, bipolar/mania, depressive psychosis and other psychoses. Top figure 
illustrates individual trajectories and overall group trajectory in healthy comparison 
subjects. Lower figure shows non-standardised differences between patients groups and 
healthy comparison subjects based on splines. Presented are also corresponding t-test 
and significance values from the generalised linear mixed model regression for the group 
and age by group interaction  
 
Cognitive measures Group comparison Test for course 





Group              t=6.33, p<0.0001 
 







Group              t=4.46, p=0.0002 
 








Group              t=3.31, p=0.0031 
 




Other psychoses  
vs.  
Controls 
Group               t=2.22, p=0.036 
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Figure 5.4 Performance IQ scores by age in healthy comparison subjects and patients with 
schizophrenia, bipolar/mania, depressive psychosis and other psychoses. Top figure 
illustrates individual trajectories and overall group trajectory in healthy comparison 
subjects. Lower figure shows non-standardised differences between patients groups and 
healthy comparison subjects based on splines. Presented are also corresponding t-test 
and significance values from the generalised linear mixed model regression for the group 
and age by group interaction  
 
Cognitive measures Group comparison Test for course 
Performance IQ   
 Schizophrenia  
vs. 
Controls 
Group              t=5.77, p<0.0001 
 








Group              t=3.56, p=0.0017 
 








Group               t=3.16, p=0.004 
 




Other psychoses  
vs.  
Controls 
Group               t=2.15, p=0.042 
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Figure 5.5 Verbal IQ scores by age in healthy comparison subjects and patients with 
schizophrenia, bipolar/mania, depressive psychosis and other psychoses. Top figure 
illustrates individual trajectories and overall group trajectory in healthy comparison 
subjects. Lower figure shows non-standardised differences between patients groups and 
healthy comparison subjects based on splines. Presented are also corresponding t-test 
and significance values from the generalised linear mixed model regression for the group 
and age by group interaction  
 
Cognitive measures Group comparison Test for course 
Verbal IQ   
 Schizophrenia  
vs. 
Controls 
Group              t=4.94, p<0.0001 
 







Group               t=3.77, p=0.001 
 





Depressive Psychosis  
vs. 
Controls 
Group               t=2.33, p=0.028 
 




Other psychoses  
vs.  
Controls 
Group               t=1.95, p=0.062 
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Figure 5.6 Learning and Memory tests scores by age in healthy comparison subjects and 
patients with schizophrenia, bipolar/mania, depressive psychosis and other psychoses. 
Top figure illustrates individual trajectories and overall group trajectory in healthy 
comparison subjects. Lower figure shows non-standardised differences between patients 
groups and healthy comparison subjects based on splines. Presented are also 
corresponding t-test and significance values from the generalised linear mixed model 
regression for the group and age by group interaction. 
 
Learning and Memory Group comparison Test for course 





Group              t=4.95, p<0.0001 
 







Group              t=1.94, p=0.065 
 







Group             t=4.31, p=0.0003 
 




Other psychoses  
vs.  
Controls 
Group               t=2.00, p=0.057 
 
Time X Group t=2.94, p=0.007 
 
 





Group         t=4.04, p=0.0005 
 






Group             t=1.25, p=0.22 
 








Group              t=1.77, p=0.09 
 
Time X Group t=2.18, p=0.039 
 
 
Other psychoses vs.  
Controls 
Group              t=1.02, p=0.031 
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Learning and Memory (cont.) Group comparison Test for course 





Group         t=4.45, p=0.0002 
 







Group              t=1.23, p=0.23 
 






Group            t=2.02, p=0.056 
 




Other psychoses  
vs.  
Controls 
Group               t=1.29, 
p=0.21 









Group              t=1.68, p=0.11 
 







Group            t=1.98, p=0.065 
 








Group              t=2.03, p=0.06 
 







Group            t=2.49, p=0.024 
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Figure 5.7 Processing Speed tests scores by age in healthy comparison subjects and 
patients with schizophrenia, bipolar/mania, depressive psychosis and other psychoses. 
Top figure illustrates individual trajectories and overall group trajectory in healthy 
comparison subjects. Lower figure shows non-standardised differences between patients 
groups and healthy comparison subjects based on splines. Presented are also 
corresponding t-test and significance values from the generalised linear mixed model 
regression for the group and age by group interaction. 
 
Processing Speed Group comparison Test for course 





Group            t=5.19, p<0.0001 
 






Group               t=2.10, p=0.047 
 







Group            t=3.39, p=0.0028 
 




Other Psychoses  
vs.  
Controls 
Group               t=1.61, p=0.12 
 
Time X Group t=2.35, p=0.027 
 
 





Group            t=4.32, p=0.0003 
 







Group            t=3.54, p=0.0018 
 








Group            t=3.57, p=0.0016 
 




Other psychoses  
vs.  
Controls 
Group               t=0.45, p=0.65 
 
Time X Group  t=0.19, p=0.85 
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Figure 5.8 Language tests scores by age in healthy comparison subjects and patients with 
schizophrenia, bipolar/mania, depressive psychosis and other psychoses. Top figure 
illustrates individual trajectories and overall group trajectory in healthy comparison 
subjects. Lower figure shows non-standardised differences between patients groups and 
healthy comparison subjects based on splines. Presented are also corresponding t-test 
and significance values from the generalised linear mixed model regression for the group 
and age by group interaction. 
 
Language Group comparison Test for course 





Group           t=4.81, p=0.0001 
 






Group              t=3.74, p=0.001 
 







Group              t=1.88, p=0.075 
 




Other psychoses  
vs.  
Controls 
Group              t=1.89, p=0.072 
 
Time X Group t=0.31, p=0.75 
 
 





Group               t=0.88, p=0.39 
 







Group               t=1.27, p=0.22 
 





Depressive Psychosis  
vs.  
Controls 
Group             t=1.70, p=0.10 
 




Other psychoses  
vs.  
Controls 
Group               t=0.28, p=0.78 
 
Time X Group  t=1.4, p=0.16 
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Figure 5.9 Executive Functions and Working Memory tests scores by age in healthy 
comparison subjects and patients with schizophrenia, bipolar/mania, depressive 
psychosis and other psychoses. Top figure illustrates individual trajectories and overall 
group trajectory in healthy comparison subjects. Lower figure shows non-standardised 
differences between patients groups and healthy comparison subjects based on splines. 
Presented are also corresponding t-test and significance values from the generalised 
linear mixed model regression for the group and age by group interaction. 
 
Executive Functions and Working Memory Group comparison Test for course 





Group           t=3.50, p=0.0024 
 






Group               t=0.24, p=0.81 
 





Group            t=4.13, p=0.0006 
 




Other psychoses  
vs.  
Controls 
Group               t=0.70, p=0.49 
 
Time X Group  t=0.84, p=0.41 
 





Group           t=3.58, p=0.0018 
 






Group               t=0.86, p=0.39 
 




Depressive Psychosis  
vs.  
Controls 
Group           t=3.09, p=0.0056 
 




Other psychoses  
vs.  
Controls 
Group               t=1.53, p=0.14 
 
Time X Group  t=1.63, p=0.11 
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Executive Functions and Working Memory (cont.) Group comparison Test for course 





Group             t=2.86, p=0.009 
 







Group               t=1.15, p=0.26 
 








Group           t=2.94, p=0.0075 
 




Other psychoses  
vs.  
Controls 
Group             t=2.65, p=0.014 
 









Group             t=2.27, p=0.033 
 







Group               t=1.20, p=0.24 
 





Depressive Psychosis  
vs.  
Controls 
Group             t=1.86, p=0.076 
 




Other psychoses  
vs.  
Controls 
Group               t=0.58, p=0.56 
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Figure 5.10 Visuospatial test scores by age in healthy comparison subjects and patients 
with schizophrenia, bipolar/mania, depressive psychosis and other psychoses. Top figure 
illustrates individual trajectories and overall group trajectory in healthy comparison 
subjects. Lower figure shows non-standardised differences between patients groups and 
healthy comparison subjects based on splines. Presented are also corresponding t-test 
and significance values from the generalised linear mixed model regression for the group 
and age by group interaction 
 
Visuospatial Group comparison Test for course 
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5.4 Discussion 
Findings from this study strongly support the hypothesis that schizophrenia is characterized by 
cognitive decline in generalized cognitive ability, especially verbal IQ. Results also demonstrate 
that different cognitive functions appear to follow different courses. Cognitive decline appears to 
be present in verbal knowledge acquisition and memory and reasoning abilities. A static 
impairment appears to characterize processing speed, visuospatial, language and executive 
function/working memory abilities. Bipolar/Mania was also characterized by cognitive decline. In 
bipolar/mania cognitive decline was evident predominantly in verbal knowledge acquisition. A 
static impairment appears to characterize processing speed, language and visuospatial abilities in 
bipolar/mania.  
 
While both schizophrenia and bipolar/mania cases showed cognitive decline beginning in late 
adolescence and continuing monotonically until the early 40‟s, schizophrenia patients already 
presented with a moderate impairment (approximately 0.5 standard deviation of impairment) in 
late adolescence. A recent meta analysis demonstrated that future schizophrenia patients have 
cognitive impairments in childhood and early adolescence which are of similar magnitude 
(Woodberry et al., 2008). In contrast, bipolar/mania cases had normal performance at late 
adolescence. Normal premorbid cognitive functioning has been described in bipolar patients 
(Koenen et al., 2009, Reichenberg et al., 2010). Bipolar/mania ended up more than 1 standard 
deviation below normal controls. 
 
In depressive psychosis patients a static impairment was evident in general intellectual ability and 
on specific cognitive measures. Interestingly there was a frequent course of later-life amelioration 
for processing speed, executive function, language and learning and memory. In patients with 
other psychoses there was no evidence for decline in general intellectual ability memory functions 
including verbal and visual presented with a deteriorating course that began later in life. A course 
of amelioration appears to apply to processing speed.  
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5.4.1 What do the findings suggest regarding the aetiology of schizophrenia? 
The neurodevelopmental model of schizophrenia posits that there is insult to the brain acquired or 
inherited in early development. In line with this model, resulting cognitive deficits are manifested 
before the onset of psychotic symptoms and should remain static even during episodic-free phase 
(Weinberger, 1987). According to the neurodegenerative model, schizophrenia is characterised 
by onset in young adulthood followed by a lengthy period of gradual cognitive decline (Klingberg 
et al., 2008). The existing literature does not provide adequate answers as to whether the 
trajectory of cognitive function over life is more consistent with a neurodevelopmental model of 
schizophrenia or a neurodegenerative pathogenesis. 
 
The findings of the current study suggest that schizophrenia involves two processes: a 
neuropathology (Weinberger, 1987) fully developed early in adult life and which remains static 
throughout adult life affecting processing speed, visuospatial, language and executive 
function/working memory abilities, and a neurodegenerative pathogenesis affecting verbal 
knowledge acquisition and memory and reasoning abilities which begins in late adolescence or 
early adult life and continuous until the 4
th
 decade of life. 
 
5.4.2 What do the findings suggest regarding the aetiology of Bipolar/Mania? 
The course of the generalized cognitive impairment in bipolar/mania patients was 
indistinguishable from that of schizophrenia patients. Deterioration was primarily evident in verbal 
knowledge acquisition. Static impairments were observed on measures of processing speed, 
language and visuospatial abilities. These findings suggest the aetiology of bipolar/mania also 
has origins in two interrelated processes: an early static one and neurodegenerative pathology. 
Models suggest partially shared aetiology between schizophrenia and bipolar disorder 
(Lichtenstein et al., 2009), and neurodevelopmental aetiologies in bipolar disorder are still 
debated (Murray et al., 2004). The present findings suggest that schizophrenia and bipolar mania 
share a neurodegenerative process but only schizophrenia presents with a neurodevelopmental 
one.   
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5.4.3 What do the findings suggest regarding the aetiology of depressive 
psychosis and other psychoses? 
The course of cognitive decline in patients with depressive psychosis was somewhat distinct from 
that of schizophrenia and bipolar/mania. Static deficits were the dominant course and were 
evident in general intellectual ability and in specific neuropsychological functions. Thus, the 
present findings suggest that a static model may be sufficient to describe the course of cognitive 
impairments in depressive psychosis.   
 
In patients with other psychoses there was no evidence for deterioration in general intellectual 
ability. However, memory functions, both verbal and visual manifested a pattern of deterioration 
which happened later in life.   
 
The findings should be interpreted in light of some limitations. The number of depressive 
psychosis and other psychoses case subjects was small, which had the practical effect of 
reducing the power to detect potentially meaningful group differences. Therefore, one should be 
cautious when interpreting the pattern of deficits in depressive and other psychotic disorders. To 
the best of my knowledge this is the first study reporting longitudinal cognitive outcome of these 
patient groups. When interpreting the different trajectories of cognitive performance across all 
diagnostic groups it should be acknowledged that certain abilities or measures for of these 
abilities may be more sensitive to global nonspecific deficits than are other abilities. The lack of 
controlling for symptoms it has to be also acknowledged. However, cognitive impairment is only 
modestly related to psychotic symptom severity and type (Harvey et al., 1998, Nieuwenstein et 
al., 2001, Tamminga et al., 1998). Cognitive impairment appears to be a relatively independent 
aspect of schizophrenia. Impairment may be evident in a subtle form from early childhood, and 
often precedes the development of psychotic symptoms. Nonetheless although the follow up 
sample was representative, it may be that more severe patients were not included in the follow up 
study (or the opposite  
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Chapter 6 General discussion 
6.1 Introduction 
Neuropsychological impairments are central features in schizophrenia and are evident in 
overwhelming majority of patients. Although several studies have examined neuropsychological 
functioning in schizophrenia at first-onset, only a limited number of studies have investigated the 
course of illness and cognition over time. It is unclear for example, whether the level of 
neuropsychological dysfunction remains relatively static or whether for some patients at least, 
there is a progressive deterioration. Even less is known about neuropsychological functioning and 
clinical course in non-schizophrenic psychotic disorders. In this investigation I compared 
neuropsychological performance between patients experiencing their first psychotic episode in the 
context of four distinct diagnostic groups. 
 
This thesis has the following specific aims:  
1) Determine the neuropsychological profile at the first episode of psychosis 
2) Examine if there are gender differences in the profile of neuropsychological performance 
3) Determine the course of neuropsychological impairment over the first decade of illness.  
 
Data comes from the AESOP (Aetiology and Ethnicity in Schizophrenia and Other Psychoses) 
study, a population based, case-control study of first episode psychosis. A comprehensive battery 
of neuropsychological tests was administrated to patients and controls twice: at baseline (for 
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6.2 Summary of findings 
6.2.1 Neuropsychological profile at the first episode of psychosis 
The principle findings are that moderate to severe neuropsychological impairments characterize 
all psychotic disorders following the first psychotic episode, and that by-and-large, the magnitude 
of impairment on specific neuropsychological functions reflects a generalized cognitive deficit. 
Differences in neuropsychological performance between patient groups and controls, and 
between the different patient groups, were largely accounted for by differences in general 
intellectual ability. Only weak correlations were observed between neuropsychological functioning 
and symptom severity. 
 
Despite the evidence that the neuropsychological impairment in psychotic disorders is 
generalized across the cognitive domains, additional specific deficits were also apparent. A 
selective deficit in working memory was evident in schizophrenic patients. In the depressive 
psychosis and other psychotic groups, a deficit beyond general intellectual impairment in verbal 
learning was evident. Finally, performance on the category (semantic) fluency test was selectively 
impaired, beyond general intellectual impairment, among patients with depressed psychosis and 
bipolar disorder or mania. 
 
6.2.2 Gender differences in the profile of neuropsychological performance 
This investigation shows that gender differences in neuropsychological functions are disorder 
specific. Both males and females with schizophrenia showed similar pervasive 
neuropsychological impairments. Males with bipolar/manic or psychotic depressive disorders 
showed no significant impairments compared with healthy controls. There was also evidence of a 
gender based domain- specific impairment in bipolar/manic disorder. Females performed 
significantly worse than males on the language domain. Gender differences were not due to 
differences in symptom severity. 
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6.2.3 The course of neuropsychological impairment over the first decade of 
illness 
Findings from this study strongly support the hypotheses that schizophrenia is characterized by 
cognitive decline in generalised cognitive ability, especially verbal IQ. Cognitive decline appears 
to characterize verbal knowledge acquisition and also memory and reasoning abilities, yet to a 
lesser extent. A static impairment evident through adult life appears to characterise processing 
speed, visuospatial, language and executive function/working memory abilities.  
 
Bipolar/Mania was also characterised by cognitive decline. Cognitive decline was evident in 
verbal knowledge acquisition. A static impairment evident through adult life appears to 
characterize processing speed, language and visuospatial abilities in bipolar/mania.  
 
In depressive psychosis patients a static impairment was evident in general intellectual ability and 
on specific cognitive measures. Interestingly there was a frequent course of later-life amelioration 
for processing speed, executive function, language and learning and memory. In patients with 
other psychoses there was no evidence for decline in general intellectual ability. Memory 
functions including verbal and visual presented with a deteriorating course that began later in life. 









- 111 - 
6.3 Strengths and limitations of this investigation 
The present investigation has several strengths. First, it is a large, first-episode psychosis study 
incorporating a population-based epidemiological sample. A limitation of most previous studies is 
that they used clinical rather than epidemiological samples. Clinical samples involve patient 
series, not complete populations. As a result, it is difficult to generalize from studies using clinical 
samples. Second, this is an ethnically diverse sample. Third, this investigation includes a 
prospective follow-up component, following patients longitudinally after a first episode of 
psychosis. Previous studies of first-episode patients were well done and sometimes had large 
samples. However, studies varied considerably in terms of the sources for case ascertainment 
(e.g., university clinics, referral centres or in-patient samples), and the age, duration of illness and 
medication status of patients. Moreover, while some studies used specific diagnostic groups, 
others examined heterogeneous groups. These issues further hinder the interpretation of this 
research and the degree to which it can be generalised. The fact that a large healthy comparison 
group was included and similarly followed longitudinally also strengthens the interpretation of my 
results. Fourth, the diagnostic procedures were blind to neuropsychological assessment. Fifth, the 
longitudinal study used diagnoses at follow up and not baseline diagnoses. This was implemented 
to increase diagnostic reliability. Another strength of this investigation is the fact that the study 
examined six major domains of cognitive function known to be affected in schizophrenia: (1) 
Learning and Memory (verbal and visual); (2) Executive functions and working memory; (3) 
Attention, concentration and mental speed; (4) Language; (5) Visual constructual/perceptual 
abilities, and (6) verbal and non-verbal general intellectual ability (IQ) and therefore methodically 
evaluated the neuropsychological profile of impairment in psychotic patients.  
 
Limitations of this investigation should, however, be acknowledged. One limitation is that no 
patients were drug naïve. Unfortunately I had insufficient information on medication to reliably 
determine dosage. Medication type or side effects could influence subjects‟ neuropsychological 
performance. However, it is an even more complex task to evaluate how the findings are affected 
by medication longitudinally when the doses of medication (antipsychotic, antidepressant, 
anticholinergic etc) might have changed dramatically or been discontinued. Nevertheless, only 
weak correlations between neuropsychological functioning and symptom severity were observed 
in the baseline study.  
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Most of the longitudinal studies are hampered by a certain dropout of patients and controls 
between the first and last assessments. Furthermore dropout to follow-up is a major source of 
information bias in studies whereby patients who are followed up differ systematically from those 
who are not followed up, or those followed for longer differ from those followed for less time. To 
reduce this type of bias I checked whether there were statistically significant differences between 
the subsamples of patients and controls that were followed up and the original cohort on 
measures of age, gender, ethnicity, education, IQ and premorbid IQ. I found that overall the 
patients from the original cohort at baseline were similar to those in the follow up in terms of the 
demographic variables. This similarity suggests that the follow up cohort is a representative 
sample of the original cohort at baseline. 
 
In this investigation cases and controls were required to be native speakers of English or to have 
migrated to the UK by age 11. The latter requirement ensured that each participant had a good 
command of English as a non-native language as they would have completed at least their 
secondary education in the UK, thus minimising the effect of linguistic or cultural biases on the 
performance of a multi-ethnic sample. In accordance with previous studies (Reichenberg et al., 
2008) cases or controls with missing data on more than three neuropsychological measures were 
excluded.  
 
Another methodological shortcoming that should be pointed out concerns the practice or learning 
effects in test-retest. This shortcoming is usually controlled by including a comparison group of 
healthy participants screened for personal or family history of psychopathology. In this study, 
healthy controls were screened for the presence of psychotic symptoms with the Psychosis 
Screening Questionnaire (Bebbington and Nayani, 1995). However, with the long intervals 
between baseline and follow-up test assessments in the longitudinal studies, any carryover effect 
that occurs is probably minimal. This assumption is supported by the healthy control group data 
from Rund et al., (Rund et al., 1993, 1997) longitudinal study. 
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6.4 Comparisons with other research 
There is considerable variability in the profile and magnitude of cognitive impairment associated 
psychosis. Even first episode patients that might represent the characteristics of schizophrenia 
more definitely have variation in the extent of impairment across neuropsychological domains 
(Kravariti et al., 2009). Some show impairment in only a few domains relative to healthy control 
participants, while others show a range of deficits in most or all domains. My results concord with 
the majority of studies (Addington et al., 2003, Albus et al., 1996, Goldberg et al., 1993, Hoff et 
al., 1992, Jeste et al., 1996, Krabbendam et al., 2005, Mohamed et al., 1999, Riley et al., 2000, 
Saykin et al., 1991) by showing that in early course of illness, cognitive impairment is present in 
all psychotic disorders but is most severe and pervasive in schizophrenia and least pervasive in 
bipolar and mania.  
 
Although there is wide acceptance that schizophrenia is accompanied by a cognitive impairment, 
there is no consensus on the precise course of the neuropsychological impairment. Rund (Rund, 
1998) in his review of longitudinal studies of cognitive functions in schizophrenia concluded that 
schizophrenia appears to be a static encephalopathy. After reviewing 15 follow-up studies he 
reported stability of cognition and no evidence of a decline, which confirms the 
neurodevelopmental view of the disorder as opposed to degeneration in schizophrenia. This 
stability mainly refers to verbal skills, memory and pre-attentional information processing. 
Moreover Bozikas and Andreou (Bozikas and Andreou, 2011) in their review of longitudinal 
studies of cognitive functions in first episode of psychosis summed up that the cognitive deficits 
that are preset at first episode of psychosis appeared to remain stable over time for periods of up 
to ten years, with a possible exception being verbal memory deficits where there is some 
evidence of further deterioration over the long time period. Longitudinally, the present findings add 
to the evidence that in multiple cognitive domains neuropsychological impairment is already 
present at the onset of illness and persists throughout adult life. Nevertheless, change, and in 
particular decline does occur, and was evident in general intellectual ability and verbal memory in 
schizophrenia. This is in concordance with studies by Hoff et al., where some neuropsychological 
functions were found to deteriorate over long time periods (Hoff et al., 1999, Hoff et al., 2005). 
The most stable cognitive domains appear to be executive function, language and 
sensory/perceptual abilities. The findings are consistent with reports in the literature (Bozikas and 
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Andreou, 2011). Whether this heterogeneity of cognitive impairment reflects specific brain 
dysfunctions within distinct genetic subtypes or individual variation in the effects of a general 
underlying pathophysiology is still not understood (Dickinson and Harvey, 2009). 
 
It is now widely accepted that cognitive abnormalities are a key feature of bipolar disorder (Arts et 
al., 2008, Bora et al., 2009, Kumar and Frangou, 2010). However, cognitive dysfunction in 
patients with bipolar disorder has been reported predominantly in chronic patients during acute 
episodes (Quraishi and Frangou, 2002). It is unclear whether cognitive impairments are present at 
illness onset. Previous studies, typically with chronic patients, have reported more severe 
impairments in schizophrenia compared to affective disorders, but qualitatively similar cognitive 
profiles (Albus et al., 1996, Reichenberg et al., 2010), particularly for psychotic affective disorders 
(Jeste et al., 1996, Mojtabai et al., 2000). Mojtabai et al., (Mojtabai et al., 2000) reported that first 
episode bipolar disorder patients performed better than schizophrenic patients in all subscales of 
the WMS, especially in the subtest of delayed visual short term memory. In the present study a 
considerable overlap was found between the patients with schizophrenia and bipolar/mania in 
terms of neuropsychological impairment, nevertheless, bipolar patients showed less severe 
decrements in performance.  
 
Studies investigating the stability of cognitive impairment in bipolar/mania patients are rare and 
available data with chronic bipolar disorder (Balanza-Martinez et al., 2005) suggest persistent 
deficits. There is evidence that certain cognitive dysfunctions are stable over time (Balanza-
Martinez et al., 2005, Mur et al., 2008) and persist during euthymia, as shown in several recent 
meta-analyses (Arts et al., 2008, Bora et al., 2009). Embedding my findings with previous 
research, it is highly likely that as proposed in schizophrenia, cognitive deficits raise from 
neurodevelopmental and neurodegenerative origin. An important distinction between 
schizophrenia and bipolar/mania, is nonetheless, the presence of continuously preserved 
functions in bipolar disorder, such as executive function and working memory. 
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Although gender differences have been reported on neuropsychological testing, the nature of 
these differences is controversial. In this investigation there were no statistically significant 
differences in neuropsychological functioning between males and females with schizophrenia or 
schizoaffective disorder. Differences in neuropsychological performance between males and 
females with bipolar/manic disorder were restricted to language functions. In psychotic depressive 
disorder females performed worse than males across neuropsychological measures. 
 
Some studies show that schizophrenic males have more cognitive deficits (especially in verbal 
processing) others show females perform worse or do not show any differences in 
neuropsychological test performance between the sexes. The findings of this investigation are 
consistent with studies reporting lack of gender differences in cognitive performance between 
schizophrenic patients and controls (Andia et al., 1995, Goldberg et al., 1995, Haas et al., 1991, 
Hoff et al., 1998). These inconsistencies in the results of studies examining gender and cognition 
in schizophrenia demonstrate many of the difficulties encountered in studies of gender and 
schizophrenia in general. Goldstein (Goldstein, 1996b) and Seidman et al. (Seidman et al., 1997) 
have suggested that samples of convenience may not include representative male and female 
patients, i.e. sex differences may not emerge if the sample consists of males and females who 
express a similar sub-type of schizophrenia. Furthermore, the specific functions assessed may 
not be the ones on which male and female differ on (Seidman et al., 1997). Hoff et al. (Hoff et al., 
1998) proposed that gender differences in cognitive performance may be due to gender 
differences in age of onset or illness severity, and if these variables are controlled, gender 
differences in cognitive performance may be insignificant. However, controlling for age of onset 
and severity of illness may lead to non representative sampling of the population of schizophrenic 
males and females as a whole. Other methodological concerns include lack of within gender 
normal comparison groups, inadequate sample sizes to test for  gender effects (as group 
differences generally exceed more subtle gender differences) and sampling of acutely ill patients 
(reflecting state rather than trait effects) (Goldstein et al., 1998, Hoff et al., 1998). Goldstein et al. 
(Goldstein et al., 1998) noted the vast majority of studies do not match schizophrenic patients with 
normal subjects within gender. Although there are significant gender differences in cognition in 
the normal population, these gender effect sizes are small, and because within gender variability 
is greater than between gender variability in normal subjects, having within gender comparison 
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groups increases the statistical power to detect gender differences in schizophrenic patients. 
Haas et al. (Haas et al., 1991) failed to find gender differences in cognitive impairment of first 
episode patients, but in patients who had been ill for 5 years or longer, males showed greater 
deficits on verbal tasks, indicative of left hemisphere dysfunction. It becomes clear that gender 
differences in cognitive function in patients with schizophrenia are not robust findings. At present 
there is no generally agreed neuropsychological profile per se of male and female schizophrenic 
patients. Whether a distinctive pattern of neuropsychological dysfunction in males and females 
exist it remains to be determined.  
 
Only of studies addressed directly the issue of gender differences in cognition in bipolar disorder. 
Barrett et al. (Barrett et al., 2008) Male patients performed worse than female patients in 
measures of spatial working memory, indicative of poor retention of visuospatial information. 
However, male patients in this study were both older and more symptomatic than female patients. 
Carrus et al., found a gender effect and an interaction between diagnosis and gender on 
immediate memory, implicating encoding and retrieval processes, both showing male bipolar 
disorder patients being disadvantaged compared with female patients and healthy controls 
(Carrus et al., 2010). The potential effect of gender was also explored in the meta-analysis by Arts 
et al., who reported smaller effect sizes for concept formation and perseveration in studies with 
higher male to female ratios (Arts et al., 2008). Although the existing evidence regarding gender 
effects on neuropsychological function in bipolar disorder is both incomplete and contradictory, 
the results of my investigation support the notion that gender related factors appear to moderate 
the severity of cognitive deficits in bipolar/mania.  
 
To my knowledge so far no study exists to address directly the issue of gender differences in 
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6.5 Integration of findings 
Despite increasing evidence of cognitive dysfunction in patients with schizophrenia and in patients 
with affective disorders, few studies have directly compared the groups longitudinally. There is 
robust evidence that cognitive deficits exist early in course of the illness in schizophrenia while 
such deficits are either nonexistent or mild in first episode of bipolar disorder (Gilvarry et al., 2001, 
Krabbendam et al., 2005, Zanelli et al., 2010). It is estimated that neuropsychological 
performance in schizophrenia patients range from one to two standard deviations below that of 
healthy comparison controls (Bilder et al., 2000, Woodberry et al., 2008). Birth cohort studies 
consistently indicate that patients with schizophrenia have premorbid cognitive impairments. 
These deficits appear absent or even reversed (i.e., superior performance) in children who will 
later develop bipolar disorder. Cannon et al., reported that preschizophreniform children showed 
deficits in cognitive function and neuromotor development but children who went on to develop 
mania by 26 years performed significantly better than controls on motor performance (Cannon et 
al., 2002a). A consequential analysis of data from the 32-year follow-up showed that higher 
childhood IQ predicted risk of later mania (Koenen et al., 2009). 
 
Integrating results from studies of premorbid functioning and current study I proposed the 
following model to describe the life course of the cognitive function in schizophrenia and 
bipolar/mania disorder. This was developed based on the available literature on premorbid 
cognitive functioning and the current findings (Cannon et al., 2002a, Cannon et al., 2000, 
Reichenberg et al., 2010).  
 
Future schizophrenia patients show impairments in general intellectual ability (IQ) early in 
development. This impairment remains static with a magnitude of about half a standard deviation 
(7 IQ points) until late adolescence (Reichenberg et al., 2010). Combining previous research on 
premorbid functioning and the current study results suggest that the IQ deficit increases in 
magnitude starting in late adolescence or early adult life (Figure 6.1). This increase in the 
magnitude of impairment is predominantly in measures relying on knowledge acquisition, and is 
reflected by increasingly greater deficits in verbal IQ. The impairment in performance IQ does not 
seem to further increase after late adolescence/early adult life. Bipolar patients present with 
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normal, or even superior IQ in childhood (Koenen et al., 2009) and also adolescence (Dunedin 
study, unpublished data, Reichenberg – Personal communication and (MacCabe et al., 2010)). As 
in schizophrenia verbal IQ begins to deteriorate in late adolescence or early adult life, and the 
resulting impairment is as severe as the one seen in schizophrenia (Figure 6.1).    
 
 
Figure 6.1 The life course trajectory of cognitive impairment in schizophrenia and 
bipolar/mania – general intellectual abilities. (Red line represents schizophrenia patients; 
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Figures 6.2 – 6.5 present the life course trajectories of cognitive functioning in schizophrenia and 
bipolar disorder on specific neuropsychological domains: Memory, language, working memory 
and executive functions and processing speed. Both schizophrenia and bipolar/mania show intact 
memory functions in childhood and adolescence. (Figure 6.2). Memory functions begin to 
deteriorate in schizophrenia in late adolescence/early adult life, a processes which possibly 
continuous throughout their adult life, at least for some specific functions. In contrast, patients with 
bipolar/mania show intact memory functions until late in adult life (Figure 6.2).  
 
 
Figure 6.2 The life course trajectory of cognitive impairment in schizophrenia and 
bipolar/mania – memory. (Red line represents schizophrenia patients; Orange line 
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Future schizophrenia patients exhibit impairments on language abilities which are already present 
in childhood (Figure 6.3). In contrast, patients with bipolar/mania show normal or even superior 
language abilities in childhood which then begin to deteriorate. This process continues until early 
adult life and remains static thereafter. (Figure 6.3).  
 
 
Figure 6.3 The life course trajectory of cognitive impairment in schizophrenia and 
bipolar/mania – language. (Red line represents schizophrenia patients; Orange line 
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On cognitive tests assessing working memory and executive function, future schizophrenia 
patients are impaired early in development. This impairment becomes static after adolescence or 
early adult life (Figure 6.4). In bipolar/mania, there is no impairment in working memory and 
executive function but there might be some decline on these functions later in life (Figure 6.4) 
 
 
Figure 6.4 The life course trajectory of cognitive impairment in schizophrenia and 
bipolar/mania – working memory and executive function. (Red line represents 
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In case of processing speed, it appears that future schizophrenia patients begin to decline from 
childhood and continue to decline until adulthood. This impairment does not seem to further 
increase in magnitude and remains static throughout adult life (Figure 6.5). However, 
bipolar/mania patients are unimpaired in childhood but seem to decline from early adolescence 
until adulthood. Thereafter this impairment is static as in schizophrenia patients (Figure 6.5).  
 
 
Figure 6.5 The life course trajectory of cognitive impairment in schizophrenia and 
bipolar/mania – processing speed. (Red line represents schizophrenia patients; Orange 






Thus, both schizophrenia and bipolar/mania patients show dynamic changes in general and 
specific cognitive functions which start early in childhood and continue across the life span. 
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Recently developmental studies in psychiatry are shifting from exploring risk factors (e.g., from 
studying whether low IQ predicts onset of psychotic illness) to examining models that can essay 
age-related changes in brain function. Although individuals with schizophrenia and individuals 
with bipolar/mania share multiple cognitive impairments, the findings from this study show a clear 
distinction between schizophrenia and bipolar/mania in the life course trajectory of cognitive 
impairment. Future research should explore the pathogenic mechanisms underlying the different 
trajectory of cognitive impairment. 
 
The findings should be interpreted in light of some limitations. The literature in mania argues that 
the number of episodes predicts the cognitive impairment. However, there was no reliable data on 
number and duration of manic episodes. Both depressive psychosis and other psychotic disorders 
show different age related changes than schizophrenia or bipolar/mania. However because of 
small sample size and luck of studies examining the premorbid period therefore it is difficult to 
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6.6 Future directions 
Additional studies are needed to investigate the impact of gender differences on cognitive deficits 
across psychotic disorders. If future research should conclusively establish progressive 
neuropsychological decline in a subset of schizophrenic patients, question arise as to why only a 
minority are so affected. Is this another example of the heterogeneous manifestations of a 
common disease (Andreasen, 1999, Palmer et al., 1999) or other factors are involved, for 
example treatment history or comorbid conditions. 
 
Future research should aim to understand the pathogenic mechanisms underlying the different 
courses of cognitive deficits in psychotic patients. Also the time pattern of cognitive decline over 
life needs to be further explored. Those cognitive deficits that are fixed and those that are most 
sensitive to change have to be indentified in order to facilitate the assessment of interventions, 
pharmacological treatments and/or cognitive rehabilitation programmes, aiming at the 
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